

# Giovanni Martinelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2886086/publications.pdf>

Version: 2024-02-01

1,149  
papers

43,481  
citations

2538

96  
h-index

3815

178  
g-index

1168  
all docs

1168  
docs citations

1168  
times ranked

30676  
citing authors

#	ARTICLE	IF	CITATIONS
1	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
2	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006, 108, 28-37.	0.6	1,117
3	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 740-753.	13.9	1,047
4	International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. <i>Blood</i> , 2015, 126, 291-299.	0.6	982
5	Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition. <i>Circulation</i> , 2006, 114, 2474-2481.	1.6	875
6	Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy. <i>Circulation</i> , 2004, 109, 2749-2754.	1.6	797
7	Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	13.9	796
8	Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. <i>Journal of Clinical Oncology</i> , 2009, 27, 4555-4562.	0.8	613
9	Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia. <i>New England Journal of Medicine</i> , 2005, 353, 977-987.	13.9	571
10	The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. <i>Blood</i> , 2013, 121, 4439-4442.	0.6	546
11	Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. <i>Blood</i> , 2004, 103, 4416-4423.	0.6	531
12	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. <i>Blood</i> , 2011, 118, 1208-1215.	0.6	486
13	Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 7374-7379.	3.2	475
14	Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. <i>Journal of the American College of Cardiology</i> , 2000, 36, 517-522.	1.2	463
15	Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 20-27.	0.8	420
16	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1&2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1061-1075.	5.1	402
17	Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. <i>Blood</i> , 2001, 97, 3658-3661.	0.6	401
18	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 6521-6528.	0.6	395

#	ARTICLE	IF	CITATIONS
19	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2003, 102, 2741-2745.	0.6	391
20	Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 680-686.	1.5	360
21	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. <i>Blood</i> , 2011, 118, 3273-3279.	0.6	356
22	ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4100-4109.	0.8	350
23	Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. <i>Blood</i> , 2007, 110, 2309-2315.	0.6	349
24	Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1795-1802.	0.8	348
25	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. <i>Blood</i> , 2011, 117, 1141-1145.	0.6	344
26	Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. <i>Blood</i> , 2007, 109, 3676-3678.	0.6	336
27	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 984-997.	5.1	330
28	Chronic myeloid leukemia and interferon- $\gamma$ : a study of complete cytogenetic responders. <i>Blood</i> , 2001, 98, 3074-3081.	0.6	309
29	Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Journal of Clinical Oncology</i> , 2009, 27, 4204-4210.	0.8	292
30	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010, 116, 3171-3179.	0.6	290
31	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. <i>Blood</i> , 2008, 111, 1834-1839.	0.6	284
32	Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. <i>Leukemia</i> , 2015, 29, 999-1003.	3.3	280
33	IKZF1 (Ikaros) Deletions in BCR-ABL1-Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 5202-5207.	0.8	276
34	Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-Helicobacter Pylori Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 1979-1983.	0.8	265
35	Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. <i>Clinical Cancer Research</i> , 2016, 22, 868-876.	3.2	262
36	Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98. <i>Journal of Clinical Oncology</i> , 2010, 28, 4480-4484.	0.8	218

#	ARTICLE	IF	CITATIONS
37	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. <i>Leukemia</i> , 2013, 27, 107-112.	3.3	212
38	N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?. <i>Clinical Chemistry</i> , 2005, 51, 1405-1410.	1.5	207
39	MDM2 inhibition: an important step forward in cancer therapy. <i>Leukemia</i> , 2020, 34, 2858-2874.	3.3	207
40	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 889-903.	5.1	205
41	Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. <i>Annals of Oncology</i> , 2008, 19, 233-241.	0.6	203
42	Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. <i>Blood</i> , 2009, 114, 4933-4938.	0.6	203
43	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1+ positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). <i>Blood</i> , 2009, 114, 2159-2167.	0.6	201
44	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR+ positive hypereosinophilic syndrome. Results of a multicenter prospective study. <i>Haematologica</i> , 2007, 92, 1173-1179.	1.7	198
45	Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 565-572.	0.8	198
46	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFR+ positive chronic eosinophilic leukemia. <i>Blood</i> , 2007, 109, 4635-4640.	0.6	195
47	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772.	0.8	190
48	Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. <i>Leukemia</i> , 2008, 22, 2176-2183.	3.3	189
49	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. <i>Blood</i> , 2009, 113, 4497-4504.	0.6	173
50	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. <i>Haematologica</i> , 2007, 92, 401-404.	1.7	172
51	Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. <i>Blood</i> , 2007, 110, 54-58.	0.6	171
52	Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. <i>Leukemia</i> , 2007, 21, 427-438.	3.3	170
53	A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition. <i>Cell Stem Cell</i> , 2013, 12, 316-328.	5.2	167
54	Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. <i>Blood</i> , 1996, 87, 1625-1634.	0.6	162

#	ARTICLE	IF	CITATIONS
55	Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. <i>Blood</i> , 2009, 114, 2168-2171.	0.6	160
56	A randomized study of interferon- $\alpha$ versus interferon- $\beta$ and low-dose arabinosyl cytosine in chronic myeloid leukemia. <i>Blood</i> , 2002, 99, 1527-1535.	0.6	158
57	Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). <i>Journal of Clinical Oncology</i> , 2015, 33, 2523-2529.	0.8	157
58	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 1524-1533.	1.7	154
59	Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2273-2281.	0.8	153
60	Efficacy and Safety of Linezolid Compared with Vancomycin in a Randomized, Double-Blind Study of Febrile Neutropenic Patients with Cancer. <i>Clinical Infectious Diseases</i> , 2006, 42, 597-607.	2.9	153
61	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. <i>Blood</i> , 2011, 118, 167-176.	0.6	153
62	Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. <i>Blood</i> , 2013, 122, 1634-1648.	0.6	152
63	Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1999, 106, 504-509.	1.2	151
64	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20 <sup>+</sup> Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3467-3474.	0.8	149
65	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019, 134, 935-945.	0.6	148
66	Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 10-20.	0.4	146
67	Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. <i>Molecular Cancer</i> , 2018, 17, 49.	7.9	146
68	Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). <i>Annals of Oncology</i> , 2005, 16, 1675-1682.	0.6	144
69	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	0.8	143
70	The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug Resistance in Chronic Myeloid Leukemia. <i>Cancer Cell</i> , 2009, 16, 232-245.	7.7	140
71	A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. <i>Journal of Hematology and Oncology</i> , 2020, 13, 126.	6.9	135
72	Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. <i>Blood</i> , 2002, 99, 443-449.	0.6	133

#	ARTICLE	IF	CITATIONS
73	Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases. <i>Bone Marrow Transplantation</i> , 1999, 23, 533-537.	1.3	130
74	A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. <i>Blood</i> , 2009, 114, 1166-1173.	0.6	129
75	Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD mutated, relapsed or refractory AML. <i>Blood</i> , 2018, 132, 598-607.	0.6	128
76	Chronic myeloid leukemia stem cells. <i>Leukemia</i> , 2019, 33, 1543-1556.	3.3	127
77	Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. <i>Blood</i> , 2014, 123, 1309-1318.	0.6	124
78	Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib. <i>Clinical Chemistry</i> , 2004, 50, 1205-1213.	1.5	120
79	Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires <i>IKAROS</i> function. <i>Journal of Experimental Medicine</i> , 2009, 206, 1739-1753.	4.2	120
80	Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 57-65.	0.8	118
81	Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. <i>Cancer</i> , 2014, 120, 1002-1009.	2.0	116
82	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. <i>Blood</i> , 2003, 102, 1588-1594.	0.6	113
83	Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells. <i>Cancer Cell</i> , 2015, 27, 671-681.	7.7	112
84	PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). <i>Blood</i> , 2014, 124, 290-290.	0.6	112
85	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012, 120, 761-767.	0.6	110
86	Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2016, 22, 1914-1921.	3.2	110
87	Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. <i>Blood</i> , 2009, 114, 5271-5278.	0.6	109
88	Minor Increases in Plasma Troponin I Predict Decreased Left Ventricular Ejection Fraction after High-Dose Chemotherapy. <i>Clinical Chemistry</i> , 2003, 49, 248-252.	1.5	105
89	Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. <i>Leukemia</i> , 2008, 22, 147-160.	3.3	105
90	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacitidine Efficacy in Higher Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2009, 15, 5002-5007.	3.2	103

#	ARTICLE	IF	CITATIONS
91	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. <i>Blood</i> , 2011, 118, 6030-6036.	0.6	103
92	Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data. <i>BMC Bioinformatics</i> , 2016, 17, 341.	1.2	103
93	Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. <i>Lancet Haematology</i> , 2015, 2, e339-e346.	2.2	102
94	Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2016, 6, e473-e473.	2.8	101
95	Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. <i>Haematologica</i> , 2008, 93, 921-924.	1.7	100
96	A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. <i>Blood Cancer Journal</i> , 2015, 5, e350-e350.	2.8	100
97	Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. <i>Blood</i> , 2008, 112, 3847-3855.	0.6	99
98	Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16811-16816.	3.3	98
99	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2011, 117, 6793-6800.	0.6	98
100	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011, 117, 5591-5599.	0.6	97
101	Imatinib and pegylated human recombinant interferon- $\alpha$ 2b in early chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004, 104, 4245-4251.	0.6	96
102	Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. <i>Leukemia</i> , 2006, 20, 230-238.	3.3	96
103	BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. <i>Human Pathology</i> , 2009, 40, 645-652.	1.1	96
104	The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. <i>Leukemia</i> , 2011, 25, 1840-1848.	3.3	96
105	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. <i>Haematologica</i> , 2013, 98, 193-200.	1.7	96
106	A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. <i>Haematologica</i> , 2012, 97, 1085-1091.	1.7	94
107	AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. <i>Leukemia</i> , 2012, 26, 91-100.	3.3	93
108	Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <i>Haematologica</i> , 2008, 93, 1792-1796.	1.7	91

#	ARTICLE	IF	CITATIONS
109	Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2006, 12, 3037-3042.	3.2	90
110	Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. <i>Annals of Oncology</i> , 2009, 20, 1993-1999.	0.6	90
111	Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib. <i>Journal of Clinical Oncology</i> , 2012, 30, 4323-4329.	0.8	90
112	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 673-673.	0.6	90
113	Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 2611-2619.	2.0	88
114	The NF- $\kappa$ B pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance. <i>Leukemia</i> , 2006, 20, 61-67.	3.3	87
115	The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation. <i>Cancer Research</i> , 2007, 67, 4287-4294.	0.4	87
116	Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2005, 19, 628-635.	3.3	85
117	Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. <i>International Journal of Cardiology</i> , 2006, 111, 120-126.	0.8	85
118	Nuclear factor $\kappa$ B as a target for new drug development in myeloid malignancies. <i>Haematologica</i> , 2007, 92, 1224-1229.	1.7	84
119	Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells. <i>Cancer Research</i> , 2008, 68, 9394-9403.	0.4	84
120	Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. <i>Haematologica</i> , 2011, 96, 552-557.	1.7	84
121	Assessing Tumor Angiogenesis. <i>Cancer Research</i> , 2004, 64, 4373-4377.	0.4	83
122	Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw003.	3.0	82
123	Circulating Endothelial Cells as a Novel Marker of Angiogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2003, 522, 83-97.	0.8	82
124	Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. <i>Cancer</i> , 2007, 110, 1178-1186.	2.0	81
125	The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. <i>Leukemia</i> , 2007, 21, 886-896.	3.3	81
126	Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Philadelphia-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. <i>American Journal of Hematology</i> , 2010, 85, 164-170.	2.0	80



#	ARTICLE	IF	CITATIONS
127	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2018, 32, 1609-1620.	3.3	80
128	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. <i>Cancer</i> , 2017, 123, 2875-2880.	2.0	79
129	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. <i>Leukemia</i> , 2015, 29, 1823-1831.	3.3	77
130	Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. <i>Transfusion</i> , 2014, 54, 2514-2522.	0.8	75
131	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 32532-32542.	0.8	75
132	A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2011, 35, 1052-1059.	0.4	74
133	A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. <i>European Journal of Cancer</i> , 2013, 49, 290-296.	1.3	74
134	Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. <i>British Journal of Haematology</i> , 2005, 129, 677-686.	1.2	73
135	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , 2009, 94, 205-212.	1.7	73
136	IKAROS Deletions Dictate a Unique Gene Expression Signature in Patients with Adult B-Cell Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2012, 7, e40934.	1.1	73
137	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
138	A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. <i>Leukemia</i> , 2015, 29, 369-376.	3.3	72
139	Phosphoinositide-Phospholipase C $\hat{2}1$ Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 782-790.	0.8	70
140	Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study). <i>Oncologist</i> , 2014, 19, 291-298.	1.9	70
141	MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences. <i>Leukemia</i> , 2018, 32, 2152-2166.	3.3	70
142	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004, 103, 2284-2290.	0.6	69
143	3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features. <i>Haematologica</i> , 1999, 84, 690-4.	1.7	69
144	Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. <i>Haematologica</i> , 2016, 101, e185-e188.	1.7	68

#	ARTICLE	IF	CITATIONS
145	Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95. <i>Journal of Clinical Oncology</i> , 2006, 24, 370-378.	0.8	67
146	Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 887-899.	1.2	67
147	Aneuploidy: Cancer strength or vulnerability?. <i>International Journal of Cancer</i> , 2019, 144, 8-25.	2.3	66
148	The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients. <i>Leukemia</i> , 2001, 15, 903-909.	3.3	65
149	Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML1107). <i>British Journal of Haematology</i> , 2012, 156, 205-212.	1.2	65
150	Dual tyrosine kinase inhibitors in chronic myeloid leukemia. <i>Leukemia</i> , 2005, 19, 1872-1879.	3.3	64
151	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). <i>Annals of Oncology</i> , 2011, 22, 689-695.	0.6	64
152	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218.	1.3	63
153	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 99-99.	0.6	63
154	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 <sup>+</sup> cell population with intrinsic resistance to imatinib. <i>Blood</i> , 2009, 114, 5191-5200.	0.6	62
155	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. <i>Blood</i> , 2009, 114, 4939-4943.	0.6	62
156	CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1 <sup>+</sup> Positive Acute Lymphoblastic Leukemia Patients. <i>Clinical Cancer Research</i> , 2011, 17, 7413-7423.	3.2	62
157	Dissecting the role of aberrant DNA methylation in human leukaemia. <i>Nature Communications</i> , 2015, 6, 7091.	5.8	62
158	Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015, 29, 1344-1349.	3.3	62
159	Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S120-S128.	0.2	62
160	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017, 92, 37-41.	2.0	62
161	Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome-Positive Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, e51-e52.	0.8	61
162	Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/Intermediate-Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2013, 19, 3297-3308.	3.2	61

#	ARTICLE	IF	CITATIONS
163	The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. <i>Haematologica</i> , 2013, 98, 1510-1516.	1.7	61
164	CAR-T cell therapy: a potential new strategy against prostate cancer. , 2019, 7, 258.		61
165	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020, 135, 534-541.	0.6	61
166	Generation and functional characterization of human dendritic cells derived from CD34+cells mobilized into peripheral blood: comparison with bone marrow CD34+cells. <i>British Journal of Haematology</i> , 1998, 101, 756-765.	1.2	60
167	Chlorambucil <i>versus</i> observation after anti- <i>Helicobacter</i> therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. <i>British Journal of Haematology</i> , 2009, 144, 367-375.	1.2	60
168	A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2150.	1.8	60
169	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009, 113, 3428-3434.	0.6	59
170	On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. <i>Leukemia</i> , 2008, 22, 1707-1711.	3.3	58
171	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 6553-6569.	0.8	58
172	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. <i>Haematologica</i> , 2007, 92, 101-105.	1.7	57
173	A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2014, 4, e238-e238.	2.8	57
174	Rituximab and Subcutaneous 2-Chloro-2-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2233-2238.	0.8	56
175	Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 2748-2754.	0.8	56
176	Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia. <i>Journal of Clinical Oncology</i> , 2014, 32, 1463-1471.	0.8	55
177	Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts). <i>Blood</i> , 2014, 124, 116-116.	0.6	55
178	NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. <i>Haematologica</i> , 2007, 92, 1268-1269.	1.7	54
179	Liposomal daunorubicin <i>versus</i> standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 2008, 143, 681-689.	1.2	54
180	A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2008, 100, 533-541.	3.0	54

#	ARTICLE	IF	CITATIONS
181	Prevalence of <i>Chromobacter xylosoxidans</i> in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe. <i>British Journal of Haematology</i> , 2014, 164, 804-810.	1.2	54
182	Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. <i>American Journal of Hematology</i> , 2016, 91, 692-699.	2.0	54
183	The cell cycle checkpoint inhibitors in the treatment of leukemias. <i>Journal of Hematology and Oncology</i> , 2017, 10, 77.	6.9	54
184	Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. <i>Leukemia</i> , 2019, 33, 1910-1922.	3.3	54
185	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. <i>Oncotarget</i> , 2012, 3, 1615-1628.	0.8	54
186	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- $\alpha$ : 5-year outcome. <i>Haematologica</i> , 2008, 93, 770-774.	1.7	53
187	Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. <i>Blood</i> , 2011, 118, 5697-5700.	0.6	53
188	Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. <i>Haematologica</i> , 2012, 97, 907-914.	1.7	53
189	Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. <i>Oncotarget</i> , 2014, 5, 1779-1792.	0.8	53
190	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine $\pm$ idasanutlin in relapsed or refractory acute myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 807-815.	1.1	53
191	Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin. <i>Molecular Cancer</i> , 2020, 19, 69.	7.9	53
192	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	1.9	52
193	Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study. <i>Blood</i> , 2010, 116, 3955-3955.	0.6	52
194	Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. <i>Oncotarget</i> , 2016, 7, 21982-21990.	0.8	52
195	New tyrosine kinase inhibitors in chronic myeloid leukemia. <i>Haematologica</i> , 2005, 90, 534-41.	1.7	52
196	The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. <i>Haematologica</i> , 2010, 95, 1683-1690.	1.7	51
197	Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. <i>American Journal of Hematology</i> , 2015, 90, 515-523.	2.0	51
198	High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1871-1879.	2.8	49

#	ARTICLE	IF	CITATIONS
199	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> , 2013, 121, 5138-5144.	0.6	49
200	Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. <i>Journal of Clinical Oncology</i> , 2016, 34, 495-500.	0.8	49
201	Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. <i>Cancer</i> , 2019, 125, 712-725.	2.0	49
202	Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome <sup>+</sup> positive B <sup>+</sup> precursor acute lymphoblastic leukemia. <i>Cancer</i> , 2020, 126, 304-310.	2.0	49
203	In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. <i>Nature Medicine</i> , 2007, 13, 15-15.	15.2	48
204	Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008, 26, 106-111.	0.8	48
205	A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT) Tj ETQq1 1 0.784314 rgBT /Overl <i>Oncology</i> , 2016, 34, 177-183.	0.8	48
206	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019, 24, 337-348.	0.7	48
207	Genomic lesions associated with a different clinical outcome in diffuse large B <sup>+</sup> cell lymphoma treated with R <sup>+</sup> CHOP <sup>21</sup> . <i>British Journal of Haematology</i> , 2010, 151, 221-231.	1.2	47
208	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. <i>Blood Advances</i> , 2020, 4, 1082-1092.	2.5	47
209	Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. <i>Haematologica</i> , 2007, 92, 437-439.	1.7	46
210	Protein Tyrosine Phosphatase Receptor Type $\beta^3$ Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia. <i>Cancer Research</i> , 2010, 70, 8896-8906.	0.4	46
211	SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome <sup>+</sup> positive cells derived from patients with chronic myeloid leukemia. <i>Blood</i> , 2011, 118, 3634-3644.	0.6	46
212	Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment. <i>Blood</i> , 2016, 128, 345-345.	0.6	46
213	High activity <sup>90</sup> Y <sup>+</sup> rituximab tiuxetan (Zevalin <sup>®</sup> ) with peripheral blood progenitor cells support in patients with refractory/resistant B <sup>+</sup> cell non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2007, 139, 590-599.	1.2	45
214	FLT3 inhibition as tailored therapy for acute myeloid leukemia. <i>Haematologica</i> , 2003, 88, 4-8.	1.7	45
215	Advanced mast cell disease: an Italian Hematological Multicenter experience. <i>International Journal of Hematology</i> , 2008, 88, 483-488.	0.7	44
216	Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. <i>British Journal of Haematology</i> , 2005, 130, 716-725.	1.2	43

#	ARTICLE	IF	CITATIONS
217	Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2005, 131, 172-179.	1.2	43
218	The response to imatinib and interferon- $\alpha$ is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. <i>Haematologica</i> , 2010, 95, 1415-1419.	1.7	43
219	Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. <i>Leukemia Research</i> , 2018, 71, 82-88.	0.4	43
220	Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2020, 1, 134-145.	2.6	43
221	Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic Response Within 1 Year of Imatinib Therapy and Those Who Achieved Such a Response After 12 Months of Treatment. <i>Journal of Clinical Oncology</i> , 2006, 24, 454-459.	0.8	42
222	c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells. <i>Molecular Cancer Research</i> , 2011, 9, 1054-1066.	1.5	42
223	Cytogenetic and Molecular Predictors of Outcome in Acute Lymphocytic Leukemia: Recent Developments. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 133-143.	1.2	42
224	CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults. <i>Cancers</i> , 2020, 12, 303.	1.7	42
225	Mast cell leukemia: a report of ten cases. <i>Annals of Hematology</i> , 2008, 87, 505-508.	0.8	41
226	c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells. <i>Leukemia</i> , 2012, 26, 644-653.	3.3	41
227	Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2017, 102, 2104-2112.	1.7	41
228	Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy. <i>Bone Marrow Transplantation</i> , 2000, 25, 173-177.	1.3	40
229	Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF- $\kappa$ B in AML carrying NPM1 mutations. <i>Leukemia</i> , 2008, 22, 1234-1240.	3.3	40
230	Imatinib mesylate for the treatment of chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 853-864.	1.1	40
231	Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50?. <i>Oncologist</i> , 2011, 16, 868-876.	1.9	40
232	A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 334-342.	1.2	40
233	Best Practices in Chronic Myeloid Leukemia Monitoring and Management. <i>Oncologist</i> , 2016, 21, 626-633.	1.9	40
234	Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged $\geq$ 65 Years with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 102-102.	0.6	40

#	ARTICLE	IF	CITATIONS
235	Intrapericardial Treatment of Neoplastic Pericardial Effusions. <i>Herz</i> , 2000, 25, 787-793.	0.4	39
236	Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. <i>Lancet Oncology</i> , The, 2007, 8, 273-274.	5.1	39
237	PI-PLC $\beta$ -1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. <i>Leukemia</i> , 2008, 22, 198-200.	3.3	39
238	Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. <i>Haematologica</i> , 2008, 93, 1814-1821.	1.7	39
239	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. <i>Transfusion</i> , 2014, 54, 331-339.	0.8	39
240	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Etracranodal Lymphoma Study Group. <i>British Journal of Haematology</i> , 2014, 166, 69-76.	1.2	39
241	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1146-1150.	1.7	39
242	IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 639387.	1.3	39
243	PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL. <i>Blood</i> , 2007, 110, 1030-1030.	0.6	39
244	Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA). <i>Blood</i> , 2015, 126, 679-679.	0.6	39
245	Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry. <i>British Journal of Haematology</i> , 2004, 126, 675-681.	1.2	37
246	Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. <i>Leukemia Research</i> , 2010, 34, 143-147.	0.4	37
247	B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FCFR1 fusion gene. <i>Leukemia Research</i> , 2010, 34, e282-e285.	0.4	37
248	Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. <i>Hematological Oncology</i> , 2006, 24, 196-204.	0.8	36
249	Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. <i>Leukemia Research</i> , 2008, 32, 1800-1808.	0.4	36
250	Synergistic induction of PI-PLC $\beta$ 1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. <i>Leukemia</i> , 2011, 25, 271-280.	3.3	36
251	Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. <i>European Journal of Cancer</i> , 2021, 146, 107-114.	1.3	36
252	Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 494-494.	0.6	36

#	ARTICLE	IF	CITATIONS
253	e8a2 BCRâ€“ABL: more frequent than other atypical BCRâ€“ABL variants?. <i>Leukemia</i> , 2005, 19, 681-684.	3.3	35
254	Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. <i>Haematologica</i> , 2009, 94, 1758-1761.	1.7	35
255	A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. <i>Transfusion and Apheresis Science</i> , 2010, 43, 321-326.	0.5	35
256	Bellerophon: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model. <i>Bioinformatics</i> , 2012, 28, 2114-2121.	1.8	35
257	Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. <i>Leukemia</i> , 2012, 26, 2474-2482.	3.3	35
258	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 99.	6.9	35
259	Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments. <i>Frontiers in Oncology</i> , 2020, 10, 624661.	1.3	35
260	Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , 2016, 128, 1069-1069.	0.6	35
261	Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML. <i>Blood</i> , 2017, 130, 813-813.	0.6	35
262	In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue. <i>Experimental Hematology</i> , 2002, 30, 905-914.	0.2	34
263	Erucylphosphocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. <i>Leukemia</i> , 2010, 24, 687-698.	3.3	34
264	Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 53377-53391.	0.8	34
265	The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. <i>Leukemia</i> , 2018, 32, 911-919.	3.3	34
266	BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008, 112, 295-295.	0.6	34
267	Immunohistological study of transferrin receptor expression in non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1984, 58, 501-508.	1.2	33
268	Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia. <i>Molecular Pharmacology</i> , 2008, 74, 884-895.	1.0	33
269	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). <i>Oncotarget</i> , 2016, 7, 9666-9679.	0.8	33
270	5â€™UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 18.	6.9	33



#	ARTICLE	IF	CITATIONS
271	Network integration of multi-tumour omics data suggests novel targeting strategies. <i>Nature Communications</i> , 2018, 9, 4514.	5.8	33
272	A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. <i>Haematologica</i> , 2021, 106, 1828-1838.	1.7	33
273	Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies. <i>Blood</i> , 2011, 118, 424-424.	0.6	33
274	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753.	2.5	33
275	Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. <i>Journal of Hematology and Oncology</i> , 2022, 15, 10.	6.9	33
276	Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemia. <i>Leukemia</i> , 2000, 14, 22-27.	3.3	32
277	JAK2<sup>V617F</sup> mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. <i>Leukemia and Lymphoma</i> , 2009, 50, 247-253.	0.6	32
278	Analysis of Double-Star Permanent-Magnet Synchronous Generators by a General Decoupled Model. <i>IEEE Transactions on Industry Applications</i> , 2009, 45, 1416-1424.	3.3	32
279	Design Improvement of a Single-Phase Brushless Permanent Magnet Motor for Small Fan Appliances. <i>IEEE Transactions on Industrial Electronics</i> , 2010, 57, 88-95.	5.2	32
280	Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr<sup>A</sup>Abl mutations and mutational analysis. <i>Pharmacogenomics</i> , 2012, 13, 1271-1284.	0.6	32
281	Fanconi anemia gene variants in therapy-related myeloid neoplasms. <i>Blood Cancer Journal</i> , 2015, 5, e323-e323.	2.8	32
282	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. <i>Leukemia Research</i> , 2020, 88, 106283.	0.4	32
283	Interferon-alfa for chronic myeloid leukemia. <i>Seminars in Hematology</i> , 2003, 40, 22-33.	1.8	32
284	Phase 1 Cohort Expansion of Flotetuzumab, a CD123<sup>A</sup>-CD3 Bispecific Dart<sup>A</sup> Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 764-764.	0.6	32
285	Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. <i>Blood</i> , 1996, 87, 3852-3859.	0.6	31
286	Poor Outcome With Front-Line Autologous Transplantation in t(4;14) Multiple Myeloma: Low Complete Remission Rate and Short Duration of Remission. <i>Journal of Clinical Oncology</i> , 2006, 24, e4-e5.	0.8	31
287	14<sup>A</sup> Ligand Prevents Nuclear Import of c<sup>A</sup>ABL Protein in Chronic Myeloid Leukemia. <i>Traffic</i> , 2009, 10, 637-647.	1.3	31
288	Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2000, 109, 722-728.	1.2	30

#	ARTICLE	IF	CITATIONS
289	Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 123, 271-277.	1.2	30
290	c-Ab1 and Src family kinases cross-talk in regulation of myeloid cell migration. <i>FEBS Letters</i> , 2010, 584, 15-21.	1.3	30
291	The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 889-898.	1.9	30
292	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 905-913.	2.0	30
293	Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. <i>Haematologica</i> , 2001, 86, 252-9.	1.7	30
294	Basement membrane components in normal hyperplastic and neoplastic endometrium. <i>Cancer</i> , 1988, 62, 142-149.	2.0	29
295	Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases. <i>European Journal of Haematology</i> , 2008, 81, 354-363.	1.1	29
296	PKR activity is required for acute leukemic cell maintenance and growth: A role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. <i>Journal of Cellular Physiology</i> , 2009, 221, 232-241.	2.0	29
297	Distributed Optical Control Plane Architectures for Handling Transmission Impairments in Transparent Optical Networks. <i>Journal of Lightwave Technology</i> , 2009, 27, 2224-2239.	2.7	29
298	Complete paraplegia after Nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. <i>American Journal of Hematology</i> , 2010, 85, 608-608.	2.0	29
299	mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. <i>Leukemia Research</i> , 2010, 34, 641-648.	0.4	29
300	Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. <i>Blood Cancer Journal</i> , 2015, 5, e347-e347.	2.8	29
301	Path-Based Fragmentation Metric and RSA Algorithms for Elastic Optical Networks. <i>Journal of Optical Communications and Networking</i> , 2019, 11, 15.	3.3	29
302	Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutin phase 1/1b study. <i>Leukemia Research</i> , 2021, 100, 106489.	0.4	29
303	A new method of "in-cell reverse transcriptase-polymerase chain reaction" for the detection of BCR/ABL transcript in chronic myeloid leukemia patients. <i>Blood</i> , 1996, 87, 3822-3827.	0.6	28
304	Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response. <i>Clinical Cancer Research</i> , 2009, 15, 1059-1063.	3.2	28
305	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011, 90, 401-408.	0.8	28
306	Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. <i>Pharmacogenomics Journal</i> , 2013, 13, 335-341.	0.9	28

#	ARTICLE	IF	CITATIONS
307	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 125.	6.9	28
308	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. <i>Leukemia</i> , 2018, 32, 139-148.	3.3	28
309	Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.. <i>Blood</i> , 2009, 114, 1129-1129.	0.6	28
310	Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. <i>Oncotarget</i> , 2016, 7, 12951-12961.	0.8	28
311	Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. <i>Leukemia and Lymphoma</i> , 2009, 50, 925-931.	0.6	27
312	IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. <i>Leukemia</i> , 2011, 25, 178-181.	3.3	27
313	The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis. <i>Leukemia Research</i> , 2015, 39, 273-278.	0.4	27
314	P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. <i>Frontiers in Pharmacology</i> , 2016, 7, 491.	1.6	27
315	A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. <i>American Journal of Hematology</i> , 2017, 92, 82-87.	2.0	27
316	Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 655-663.	2.0	27
317	Main changes in European Clinical Trials Regulation (No 536/2014). <i>Contemporary Clinical Trials Communications</i> , 2018, 11, 99-101.	0.5	27
318	The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. <i>Leukemia</i> , 2019, 33, 2628-2639.	3.3	27
319	The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?. <i>Journal of Hematology and Oncology</i> , 2019, 12, 123.	6.9	27
320	Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. <i>Haematologica</i> , 2000, 85, 930-4.	1.7	27
321	Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. <i>Leukemia</i> , 2010, 24, 66-73.	3.3	26
322	Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. <i>Blood</i> , 2011, 117, 6923-6927.	0.6	26
323	Molecular Monitoring of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 735-740.	2.0	26
324	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. <i>Blood</i> , 2018, 132, 563-563.	0.6	26

#	ARTICLE	IF	CITATIONS
325	Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. <i>British Journal of Haematology</i> , 1999, 107, 419-428.	1.2	25
326	Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a "head-to-head comparison". <i>Leukemia and Lymphoma</i> , 2010, 51, 583-591.	0.6	25
327	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. <i>Leukemia</i> , 2019, 33, 2276-2290.	3.3	25
328	Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer. <i>Cancers</i> , 2020, 12, 2490.	1.7	25
329	Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. <i>Cancer</i> , 2021, 127, 372-380.	2.0	25
330	Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). <i>Journal of Clinical Oncology</i> , 2018, 36, 7042-7042.	0.8	25
331	CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 159.	3.5	25
332	Selection and Transplantation of Autologous Hematopoietic CD34+Cells for Patients with Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1997, 26, 1-11.	0.6	24
333	Rapid Detection of Flt3 Mutations in Acute Myeloid Leukemia Patients by Denaturing HPLC. <i>Clinical Chemistry</i> , 2003, 49, 1642-1650.	1.5	24
334	Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2006, 17, 495-502.	0.6	24
335	RAD 001 (everolimus) prevents mTOR and Akt late reactivation in response to imatinib in chronic myeloid leukemia. <i>Journal of Cellular Biochemistry</i> , 2010, 109, 320-328.	1.2	24
336	Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta. <i>American Journal of Hematology</i> , 2013, 88, 594-600.	2.0	24
337	Efficacy of <sup>90</sup> Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma. <i>Hematological Oncology</i> , 2014, 32, 10-15.	0.8	24
338	Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. <i>Leukemia Research</i> , 2014, 38, 236-242.	0.4	24
339	Relationship between genome and epigenome - challenges and requirements for future research. <i>BMC Genomics</i> , 2014, 15, 487.	1.2	24
340	Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. <i>Journal of Translational Medicine</i> , 2018, 16, 172.	1.8	24
341	PET/CT in Multiple Myeloma: Beyond FDG. <i>Frontiers in Oncology</i> , 2020, 10, 622501.	1.3	24
342	Reliability of Body Temperature Measurements Obtained with Contactless Infrared Point Thermometers Commonly Used during the COVID-19 Pandemic. <i>Sensors</i> , 2021, 21, 3794.	2.1	24

#	ARTICLE	IF	CITATIONS
343	Unravelling similarities and differences in the role of circular and linear PVT1 in cancer and human disease. <i>British Journal of Cancer</i> , 2022, 126, 835-850.	2.9	24
344	Practical Considerations in the Treatment of Hepatocellular Carcinoma. <i>Drugs</i> , 1998, 55, 367-382.	4.9	23
345	All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. <i>European Journal of Haematology</i> , 2000, 64, 139-144.	1.1	23
346	Interferon-alfa for chronic myeloid leukemia. <i>Seminars in Hematology</i> , 2003, 40, 22-33.	1.8	23
347	Imatinib mesylate in the treatment of hematologic malignancies. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1597-1611.	1.4	23
348	Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2009, 94, 102-112.	1.7	23
349	The molecular anatomy of the FIP1L1-PDGFR $\alpha$ fusion gene. <i>Leukemia</i> , 2009, 23, 271-278.	3.3	23
350	Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. <i>Leukemia</i> , 2013, 27, 907-913.	3.3	23
351	The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone. <i>Annals of Oncology</i> , 2014, 25, 176-181.	0.6	23
352	IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2015, 13, 229.	1.8	23
353	NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2015, 56, 3222-3226.	0.6	23
354	In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. <i>BMC Cancer</i> , 2016, 16, 572.	1.1	23
355	Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.. <i>Blood</i> , 2007, 110, 735-735.	0.6	23
356	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	23
357	The cytogenetic response as a surrogate marker of survival. <i>Seminars in Hematology</i> , 2003, 40, 56-61.	1.8	22
358	Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606. <i>Leukemia Research</i> , 2007, 31, 979-987.	0.4	22
359	PKR is activated in MDS patients and its subcellular localization depends on disease severity. <i>Leukemia</i> , 2008, 22, 2267-2269.	3.3	22
360	GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. <i>British Journal of Haematology</i> , 2011, 154, 564-568.	1.2	22

#	ARTICLE	IF	CITATIONS
361	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2016, 101, 1200-1207.	1.7	22
362	Dasatinib Plus Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) with Resistance or Suboptimal Response to a Prior Tyrosine Kinase Inhibitor (TKI): Phase I Study CA180323. <i>Blood</i> , 2014, 124, 4539-4539.	0.6	22
363	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. <i>Oncotarget</i> , 2017, 8, 29906-29913.	0.8	22
364	Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods. <i>Bone Marrow Transplantation</i> , 1998, 22, 1065-1070.	1.3	21
365	CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. <i>Leukemia</i> , 2008, 22, 426-428.	3.3	21
366	Novel Agents for Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 429.	1.7	21
367	A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The "START-L" CA180015 Study. <i>Blood</i> , 2005, 106, 42-42.	0.6	21
368	Line Treatment of Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Final Results of the GIMEMA LAL1205 Study. <i>Blood</i> , 2008, 112, 305-305.	0.6	21
369	Crucial factors of the inflammatory microenvironment (IL-1 <sup>2</sup> /TNF- $\alpha$ /TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an <i>in vitro</i> study. <i>Oncotarget</i> , 2016, 7, 43974-43988.	0.8	21
370	Pediatric Therapy In Adult Acute Lymphoblastic Leukemia: Updated Experience of a Single Centre. <i>Blood</i> , 2010, 116, 4338-4338.	0.6	21
371	Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR- $\alpha$ positive idiopathic hypereosinophilic syndrome. <i>Haematologica</i> , 2004, 89, 236-7.	1.7	21
372	Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. <i>European Journal of Haematology</i> , 2004, 72, 264-267.	1.1	20
373	Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2007, 136, 87-95.	1.2	20
374	Rituximab and Subcutaneous 2-Chloro-2-Deoxyadenosine as Therapy in Untreated and Relapsed Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 130-132.	0.2	20
375	Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease. <i>International Immunology</i> , 2012, 24, 583-591.	1.8	20
376	Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. <i>Leukemia Research</i> , 2014, 38, 581-585.	0.4	20
377	Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. <i>Blood</i> , 2019, 134, 14-14.	0.6	20
378	Enasidenib and ivosidenib in AML. <i>Minerva Medica</i> , 2020, 111, 411-426.	0.3	20

#	ARTICLE	IF	CITATIONS
379	Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. <i>Haematologica</i> , 2003, 88, 256-9.	1.7	20
380	Release of IFN $\gamma$ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells. <i>Clinical Cancer Research</i> , 2022, 28, 3141-3155.	3.2	20
381	Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. <i>British Journal of Cancer</i> , 2008, 98, 25-33.	2.9	19
382	Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2018, 78, 1097-1109.	0.4	19
383	Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	19
384	Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition. <i>Cancers</i> , 2019, 11, 1340.	1.7	19
385	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , 2008, 112, 181-181.	0.6	19
386	Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study. <i>Blood</i> , 2015, 126, 321-321.	0.6	19
387	Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia. <i>Leukemia</i> , 2005, 19, 470-472.	3.3	18
388	Permanent magnet axial flux disc generator for small wind turbines. , 2008, , .		18
389	Primary role of multiparametric flow cytometry in the diagnostic workup of indolent clonal mast cell disorders. <i>Cytometry Part B - Clinical Cytometry</i> , 2011, 80B, 362-368.	0.7	18
390	Plerixafor and Filgrastim XM02 (Tevagastim <sup>®</sup> ) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidate to autologous bone marrow transplantation. <i>European Journal of Haematology</i> , 2012, 88, 154-158.	1.1	18
391	A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. <i>Leukemia Research</i> , 2013, 37, 1100-1106.	0.4	18
392	The relevance of a low <i>JAK2</i> V617F allele burden in clinical practice: a monocentric study. <i>Oncotarget</i> , 2017, 8, 37239-37249.	0.8	18
393	An SDN-enabled multi-layer protection and restoration mechanism. <i>Optical Switching and Networking</i> , 2018, 30, 23-32.	1.2	18
394	Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2019, 11, 1654.	1.7	18
395	Accuracy of Mobile Applications versus Wearable Devices in Long-Term Step Measurements. <i>Sensors</i> , 2020, 20, 6293.	2.1	18
396	Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with <i>FLT3</i> -mutated ( <i>FLT3</i> mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial. <i>Cancer Research</i> , 2019, 79, CT184-CT184.	0.4	18

#	ARTICLE	IF	CITATIONS
397	Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study. <i>Blood</i> , 2011, 118, 269-269.	0.6	18
398	Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7100-7100.	0.8	18
399	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. <i>Oncotarget</i> , 2015, 6, 31284-31294.	0.8	18
400	The IKK Inhibitor PS1145 Allows to Overcome Imatinib Resistance.. <i>Blood</i> , 2004, 104, 2940-2940.	0.6	18
401	FEM calculation of the LSM propulsion force in EMS-MAGLEV trains. <i>IEEE Transactions on Magnetics</i> , 1996, 32, 5064-5066.	1.2	17
402	Hypereosinophilic Syndrome and Molecularly Targeted Therapy. <i>Seminars in Hematology</i> , 2007, 44, S4-S16.	1.8	17
403	The Role of Dosimetry in the High Activity 90Y-Ibritumomab Tiuxetan Regimens: Two Cases of Abnormal Biodistribution. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 271-275.	0.7	17
404	Absence of bidirectional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of <i>MPL</i> polymorphisms. <i>British Journal of Haematology</i> , 2013, 161, 142-144.	1.2	17
405	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1951.	1.7	17
406	Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia. <i>European Journal of Haematology</i> , 2020, 104, 299-309.	1.1	17
407	Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. <i>Cancers</i> , 2021, 13, 840.	1.7	17
408	CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2639.	1.7	17
409	Safety of FLT3 inhibitors in patients with acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 851-865.	1.0	17
410	Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine. <i>Blood</i> , 2013, 122, 498-498.	0.6	17
411	Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 <i>START-LA</i> ™ study. <i>Journal of Clinical Oncology</i> , 2006, 24, 6528-6528.	0.8	17
412	Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative) <i>TJ ETQq0 0 0 rgBTg/Overlor 10 Tf 50</i>		
413	Early detection of bone marrow engraftment by amplification of hypervariable DNA regions. <i>Haematologica</i> , 1997, 82, 156-60.	1.7	17
414	Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. <i>The Hematology Journal</i> , 2004, 5, 168-177.	2.0	16



#	ARTICLE	IF	CITATIONS
415	Signalling-Based Architectures for Impairment-Aware Lightpath Set-Up in GMPLS Networks. , 2007, , .		16
416	Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy. Nature Clinical Practice Oncology, 2009, 6, 68-69.	4.3	16
417	Magnetic resonance imaging of primary breast lymphoma. Radiologia Medica, 2009, 114, 915-924.	4.7	16
418	New targets for Ph+ leukaemia therapy. Best Practice and Research in Clinical Haematology, 2009, 22, 445-454.	0.7	16
419	Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer, 2013, 13, 173.	1.1	16
420	Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups. Blood Cancer Journal, 2013, 3, e147-e147.	2.8	16
421	The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. Blood, 2015, 125, 600-605.	0.6	16
422	Germline polymorphisms and survival of lung adenocarcinoma patients: A genome-wide study in two European patient series. International Journal of Cancer, 2015, 136, E262-71.	2.3	16
423	Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. Leukemia, 2016, 30, 1615-1619.	3.3	16
424	Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. BMC Cancer, 2018, 18, 1117.	1.1	16
425	Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study. Bone Marrow Transplantation, 2019, 54, 717-725.	1.3	16
426	Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. Transplantation and Cellular Therapy, 2021, 27, 153-162.	0.6	16
427	Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase II Trial.. Blood, 2004, 104, 130-130.	0.6	16
428	FoxO Transcription Factor Is Delocalized and Inactivated in Acute Myeloid Leukaemia Patients.. Blood, 2007, 110, 1251-1251.	0.6	16
429	Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.. Blood, 2007, 110, 473-473.	0.6	16
430	Dasatinib as Front-Line Monotherapy for the Induction Treatment of Adult and Elderly Ph+ Acute Lymphoblastic Leukemia (ALL) Patients: Interim Analysis of the GIMEMA Prospective Study LAL1205.. Blood, 2007, 110, 7-7.	0.6	16
431	Stability of Conversion Factors for BCR-ABL Monitoring -â€“ Implications for the Frequency of Validation Rounds. Blood, 2010, 116, 893-893.	0.6	16
432	Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.. Haematologica, 2007, 92, 1721-1722.	1.7	15

#	ARTICLE	IF	CITATIONS
433	The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. <i>Annals of Oncology</i> , 2009, 20, 1344-1351.	0.6	15
434	<sc>DNA</sc> hypermethylation promotes the low expression of pro-apoptotic <i>BCL2L1</i> associated with <i>BCR</i> <i>ABL1</i> fusion gene of chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 373-376.	1.2	15
435	Chibby drives $\beta$ catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells. <i>Cellular Signalling</i> , 2013, 25, 1820-1827.	1.7	15
436	Core needle biopsy as a front line diagnostic approach for lymphoma patients. <i>Hematological Oncology</i> , 2015, 33, 247-249.	0.8	15
437	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536.	1.7	15
438	Clinical and Experimental Efficacy of Gemtuzumab Ozogamicin in Core Binding Factor Acute Myeloid Leukemia. <i>Hematology Reports</i> , 2017, 9, 7028.	0.3	15
439	Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2018, 97, 1767-1774.	0.8	15
440	Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients. <i>Haematologica</i> , 2020, 105, e13-e16.	1.7	15
441	Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. <i>Leukemia</i> , 2021, 35, 2813-2826.	3.3	15
442	Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib. <i>Journal of Clinical Oncology</i> , 2007, 25, 7006-7006.	0.8	15
443	The human Smoothed inhibitor PF-04449913 induces exit from quiescence and loss of multipotent <i>Drosophila</i> hematopoietic progenitor cells. <i>Oncotarget</i> , 2016, 7, 55313-55327.	0.8	15
444	A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma.. <i>Blood</i> , 2010, 116, 2803-2803.	0.6	15
445	Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 303-10.	0.3	15
446	Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments. <i>Cancers</i> , 2022, 14, 2408.	1.7	15
447	Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. <i>Bone Marrow Transplantation</i> , 2007, 39, 189-191.	1.3	14
448	Rituximab in Lymphocyte-Predominant Hodgkin Disease. <i>Oncology</i> , 2009, 76, 26-29.	0.9	14
449	Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience. <i>Leukemia Research</i> , 2011, 35, 712-714.	0.4	14
450	BCR-ABL1-Associated Reduction of Beta Catenin Antagonist Chibby1 in Chronic Myeloid Leukemia. <i>PLoS ONE</i> , 2013, 8, e81425.	1.1	14

#	ARTICLE	IF	CITATIONS
451	Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment. <i>Hematology Reports</i> , 2014, 6, 5554.	0.3	14
452	Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. <i>American Journal of Hematology</i> , 2014, 89, 119-124.	2.0	14
453	New generation anaplastic lymphoma kinase inhibitors. <i>Translational Lung Cancer Research</i> , 2019, 8, S280-S289.	1.3	14
454	Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 565857.	1.3	14
455	Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells. <i>Frontiers in Oncology</i> , 2020, 10, 1225.	1.3	14
456	Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients. <i>Diagnostics</i> , 2020, 10, 269.	1.3	14
457	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , 2010, 116, 359-359.	0.6	14
458	The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. <i>Blood</i> , 2012, 120, 1678-1678.	0.6	14
459	FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives. <i>Minerva Medica</i> , 2020, 111, 427-442.	0.3	14
460	Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 15.	2.8	14
461	Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells. <i>Haematologica</i> , 1999, 84, 397-404.	1.7	14
462	A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. <i>Haematologica</i> , 1999, 84, 707-15.	1.7	14
463	Efficacy of Vinblastine, Bleomycin, Methotrexate (VBM) Combination Chemotherapy with Involved Field Radiotherapy in Early Stage (I-IIA) Hodgkin Disease Patients. <i>Leukemia and Lymphoma</i> , 2003, 44, 1919-1923.	0.6	13
464	Extramedullary Myeloid Sarcoma of the Breast. <i>Journal of Clinical Oncology</i> , 2008, 26, 4041-4043.	0.8	13
465	Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge. <i>Leukemia and Lymphoma</i> , 2008, 49, 159-162.	0.6	13
466	A calpain-cleaved fragment of $\beta$ -catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib. <i>Cellular Signalling</i> , 2014, 26, 1690-1697.	1.7	13
467	Present and future of molecular monitoring in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 173, 337-349.	1.2	13
468	FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. <i>Leukemia and Lymphoma</i> , 2017, 58, 372-381.	0.6	13

#	ARTICLE	IF	CITATIONS
469	Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 605-616.	1.0	13
470	Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015).. <i>Blood</i> , 2007, 110, 2810-2810.	0.6	13
471	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. <i>Blood</i> , 2008, 112, 185-185.	0.6	13
472	CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. <i>Blood</i> , 2008, 112, 3187-3187.	0.6	13
473	Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. <i>Haematologica</i> , 2002, 87, 1036-40.	1.7	13
474	t(8;14)(q11;q32) in acute lymphoid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1993, 67, 55-58.	1.0	12
475	Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon- $\beta$ -based therapy. <i>Bone Marrow Transplantation</i> , 2000, 25, 729-736.	1.3	12
476	Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190BCR-ABL-positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2002, 16, 2159-2160.	3.3	12
477	Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. <i>Annals of Oncology</i> , 2003, 14, 554-558.	0.6	12
478	Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine. <i>Leukemia and Lymphoma</i> , 2006, 47, 1091-1102.	0.6	12
479	Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 1011-1022.	1.4	12
480	Successful combination treatment of clofarabine, cytarabine, and gemtuzumab+ozogamicin in adult refractory B $\alpha$ acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2009, 84, 849-850.	2.0	12
481	Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. <i>Leukemia</i> , 2009, 23, 1370-1371.	3.3	12
482	Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2 $\alpha$ -deoxyadenosine (2-CdA) and Rituximab. <i>Leukemia Research</i> , 2010, 34, 454-457.	0.4	12
483	Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies. <i>European Radiology</i> , 2011, 21, 63-69.	2.3	12
484	FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3968-3975.	1.2	12
485	Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens. <i>Frontiers in Oncology</i> , 2021, 11, 643490.	1.3	12
486	Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer. <i>Pharmaceuticals</i> , 2021, 14, 457.	1.7	12

#	ARTICLE	IF	CITATIONS
487	A Study of Connection Management Approaches for an Impairment-Aware Optical Control Plane. Lecture Notes in Computer Science, 2007, , 229-238.	1.0	12
488	High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.. Blood, 2005, 106, 488-488.	0.6	12
489	Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types.. Blood, 2007, 110, 320-320.	0.6	12
490	A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-ltd Positive Acute Myeloid Leukemia: Updated Interim Results. Blood, 2011, 118, 2576-2576.	0.6	12
491	Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10. Blood, 2014, 124, 799-799.	0.6	12
492	Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis. Blood, 2008, 112, 188-188.	0.6	12
493	Molecular therapy for multiple myeloma. Haematologica, 2001, 86, 908-17.	1.7	12
494	Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient. Leukemia, 1999, 13, 1463-1464.	3.3	11
495	Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio. Haematologica, 2007, 92, 429-430.	1.7	11
496	Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leukemia and Lymphoma, 2010, 51, 1485-1493.	0.6	11
497	Who should be really considered as a poor mobilizer in the plerixafor era?. Transfusion and Apheresis Science, 2012, 47, 27-32.	0.5	11
498	Molecular Monitoring. Current Hematologic Malignancy Reports, 2014, 9, 1-8.	1.2	11
499	Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia. Haematologica, 2015, 100, e14-e17.	1.7	11
500	Chlorambucilâ€“rituximab as firstâ€“line therapy in patients affected by follicular nonâ€“Hodgkin's lymphoma: a retrospective singleâ€“centre study. Hematological Oncology, 2015, 33, 129-135.	0.8	11
501	Comparison of <i>JAK2</i> <sup>V617F</sup> -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. Hematological Oncology, 2018, 36, 269-275.	0.8	11
502	Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. Journal of Experimental and Clinical Cancer Research, 2019, 38, 216.	3.5	11
503	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology, 2019, 94, 408-416.	2.0	11
504	Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model. Cells, 2020, 9, 2666.	1.8	11

#	ARTICLE	IF	CITATIONS
505	Monoclonal antibodies in multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 21-27.	0.2	11
506	High Dose 90Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.. <i>Blood</i> , 2006, 108, 2720-2720.	0.6	11
507	Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. <i>Blood</i> , 2009, 114, 3292-3292.	0.6	11
508	Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis. <i>Blood</i> , 2010, 116, 861-861.	0.6	11
509	Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis. <i>Blood</i> , 2013, 122, 2622-2622.	0.6	11
510	First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients. <i>Blood</i> , 2014, 124, 797-797.	0.6	11
511	Traffic Independent Heuristics for Regenerator Site Selection for Providing Any-to-Any Optical Connectivity. , 2010, , .		11
512	Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. <i>Biologics: Targets and Therapy</i> , 2007, 1, 121-7.	3.0	11
513	Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis. <i>Haematologica</i> , 1998, 83, 593-601.	1.7	11
514	Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. <i>Haematologica</i> , 2000, 85, 653-8.	1.7	11
515	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 327.	0.6	10
516	The Effect of Progestin on Factors Influencing Growth and Invasion of Endometrial Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 1991, 622, 463-468.	1.8	10
517	ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 801-806.	0.6	10
518	ChIVPP/ABVVP, a first line "hybrid"™ combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. <i>British Journal of Haematology</i> , 2004, 125, 584-589.	1.2	10
519	Advances in the treatment for haematological malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 721-732.	0.9	10
520	A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. <i>Hematological Oncology</i> , 2009, 27, 154-159.	0.8	10
521	Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia. <i>Leukemia</i> , 2009, 23, 405-406.	3.3	10
522	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide+dexamethasone incorporated into double autologous transplantation. <i>Annals of Hematology</i> , 2013, 92, 1271-1280.	0.8	10

#	ARTICLE	IF	CITATIONS
523	Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia. <i>Current Cancer Drug Targets</i> , 2013, 13, 791-810.	0.8	10
524	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2016, 91, 617-622.	2.0	10
525	Adrenomedullin in the growth modulation and differentiation of acute myeloid leukemia cells. <i>International Journal of Oncology</i> , 2016, 48, 1659-1669.	1.4	10
526	Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers. <i>Disease Markers</i> , 2018, 2018, 1-8.	0.6	10
527	Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?. <i>Journal of Oncology</i> , 2019, 2019, 1-6.	0.6	10
528	Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement. <i>Lung Cancer</i> , 2020, 142, 47-50.	0.9	10
529	Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. <i>Cancers</i> , 2021, 13, 4566.	1.7	10
530	Long Term Follow-Up of the Gimema GSI 103 AMLE Randomized Trial: Daunoxome Seems To Improve Disease-Free Survival (DFS) of Elderly Patients with Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2006, 108, 1979-1979.	0.6	10
531	Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).. <i>Blood</i> , 2006, 108, 3081-3081.	0.6	10
532	A Randomized Phase 3 Study of Tipifarnib Compared to Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients 70 Years or Older.. <i>Blood</i> , 2007, 110, 439-439.	0.6	10
533	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma. <i>Blood</i> , 2014, 124, 1718-1718.	0.6	10
534	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2016, 128, 3070-3070.	0.6	10
535	An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7067-TPS7067.	0.8	10
536	A Framework for Regenerator Site Selection Based on Multiple Paths. , 2010, , .		10
537	Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future. <i>Minerva Medica</i> , 2020, 111, 395-410.	0.3	10
538	Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.. <i>Blood</i> , 2008, 112, 957-957.	0.6	10
539	Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis. <i>Blood</i> , 2014, 124, 3141-3141.	0.6	10
540	Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow. <i>British Journal of Haematology</i> , 1998, 101, 119-129.	1.2	9

#	ARTICLE	IF	CITATIONS
541	Imatinib mesylate in the treatment of c-kit <sup>+</sup> positive acute myeloid leukemia: is this the real target?. <i>Blood</i> , 2005, 105, 904-905.	0.6	9
542	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , 2009, 50, 114-118.	0.6	9
543	Patient with ataxia telangiectasia who developed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 1818-1820.	0.6	9
544	Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. <i>Leukemia and Lymphoma</i> , 2013, 54, 1151-1158.	0.6	9
545	14-3-3 Binding and Sumoylation Concur to the Down-Modulation of $\beta$ -catenin Antagonist chibby 1 in Chronic Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0131074.	1.1	9
546	Opposite activation of the Hedgehog pathway in CD138 <sup>+</sup> plasma cells and CD138 <sup>+</sup> CD19 <sup>+</sup> B cells identifies two subgroups of patients with multiple myeloma and different prognosis. <i>Leukemia</i> , 2016, 30, 1869-1876.	3.3	9
547	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. <i>Future Oncology</i> , 2018, 14, 2713-2723.	1.1	9
548	Analysis of Glucose Profiles in Imatinib-Resistant or Intolerant Chronic Myelogenous Leukemia (CML) Patients (pts) Treated with Nilotinib: Lack of Correlation between Glucose Levels and Nilotinib Efficacy.. <i>Blood</i> , 2007, 110, 4588-4588.	0.6	9
549	The Molecular Pathogenesis of Multiple Myeloma. <i>Hematology Reports</i> , 2020, 12, 9054.	0.3	9
550	A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients. <i>Blood</i> , 2010, 116, 4848-4848.	0.6	9
551	Droplet Digital PCR for BCR <sup>+</sup> ABL1 Monitoring in Diagnostic Routine: Ready to Start?. <i>Cancers</i> , 2021, 13, 5470.	1.7	9
552	Optimization of the winding configuration in EDS-MAGLEV trains. <i>IEEE Transactions on Magnetics</i> , 1996, 32, 2393-2398.	1.2	8
553	Interleukin-9 in Human Myeloid Leukemia Cells. <i>Leukemia and Lymphoma</i> , 1997, 26, 563-573.	0.6	8
554	Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. <i>British Journal of Haematology</i> , 2006, 134, 356-356.	1.2	8
555	cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 349-360.	1.1	8
556	Chromosome instability and translocation t(11;18) in primary gastric marginal zone B <sup>+</sup> cell lymphoma of MALT <sup>+</sup> type. <i>Hematological Oncology</i> , 2007, 25, 184-188.	0.8	8
557	Long-term molecular complete remission with IFN- $\alpha$ in Ph <sup>+</sup> adult acute lymphoid leukemia patients. <i>Leukemia</i> , 2008, 22, 1617-1618.	3.3	8
558	New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2009, 2, 297-303.	1.0	8



#	ARTICLE	IF	CITATIONS
559	Management of Anaplastic Large-Cell Lymphoma During Pregnancy. <i>Journal of Clinical Oncology</i> , 2009, 27, e75-e77.	0.8	8
560	Sexuality in patients undergoing haematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2011, 94, 519-524.	0.7	8
561	BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy. <i>Blood Cancer Journal</i> , 2011, 1, e30-e30.	2.8	8
562	Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2012, 2, e61-e61.	2.8	8
563	Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL. <i>British Journal of Haematology</i> , 2014, 164, 299-302.	1.2	8
564	DNA Methyltransferase 1 Drives Transcriptional Down-Modulation of $\beta$ 2 Catenin Antagonist Chibby1 Associated With the BCR-ABL1 Gene of Chronic Myeloid Leukemia. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 589-597.	1.2	8
565	Single Nucleotide Polymorphisms as Genomic Markers for High-Throughput Pharmacogenomic Studies. <i>Methods in Molecular Biology</i> , 2016, 1368, 143-159.	0.4	8
566	Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells. <i>Haematologica</i> , 2017, 102, 1204-1214.	1.7	8
567	BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. <i>Leukemia</i> , 2021, 35, 2102-2107.	3.3	8
568	Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 632231.	1.3	8
569	Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis. <i>Cancer Medicine</i> , 2021, 10, 2601-2610.	1.3	8
570	Heterogeneous self-tracked health and fitness data integration and sharing according to a linked open data approach. <i>Computing (Vienna/New York)</i> , 2022, 104, 835-857.	3.2	8
571	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 44-44.	0.6	8
572	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party. <i>Blood</i> , 2009, 114, 2205-2205.	0.6	8
573	Improved Detection of the KIT D816V Mutation Using a Real-Time PCR Assay Allows a Finer Recognition of Patients with Indolent Systemic Mastocytosis. <i>Blood</i> , 2011, 118, 5163-5163.	0.6	8
574	Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation. <i>Blood</i> , 2018, 132, 2639-2639.	0.6	8
575	Structural Organization of BCR-ABL Gene in Chronic Phase and Blast Transformation in Chronic Myeloid Leukemia Patients. <i>Leukemia and Lymphoma</i> , 1993, 11, 51-56.	0.6	7
576	Idarubicin Containing Regimen in Multiple Myeloma: Preliminary Results of a Pilot Study Using a Modified "TANDEM" Transplant Program. <i>Leukemia and Lymphoma</i> , 2003, 44, 299-302.	0.6	7

#	ARTICLE	IF	CITATIONS
577	Control strategies for a VAWT driven PM synchronous generator. , 2008, , .		7
578	New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells. Investigational New Drugs, 2010, 28, 876-878.	1.2	7
579	Chronic myeloid leukemia: the basis of treatment for tomorrow. Haematologica, 2011, 96, 1737-1739.	1.7	7
580	A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. Leukemia and Lymphoma, 2011, 52, 2329-2335.	0.6	7
581	Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome. Hematology Reports, 2013, 5, 7.	0.3	7
582	Primary cardiac lymphoma with isolated parenchymal central nervous system relapse: report of two cases and review of the literature. Ecancermedicalscience, 2014, 8, 474.	0.6	7
583	Handling race conditions among bidirectional LSP requests via WA-method-TLV in GMPLS WDM networks. , 2014, , .		7
584	Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry. Biology of Blood and Marrow Transplantation, 2014, 20, 501-506.	2.0	7
585	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. British Journal of Haematology, 2018, 183, 35-46.	1.2	7
586	Treatment-Free Remission in Chronic Myeloid Leukemia: Lights and Shadows. Hematology Reports, 2020, 12, 8950.	0.3	7
587	Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art. Frontiers in Oncology, 2020, 10, 592487.	1.3	7
588	Identification of a novel RAB3IP&HMG2 fusion transcript in an adult head and neck rhabdomyosarcoma. Oral Diseases, 2022, 28, 2052-2054.	1.5	7
589	Autologous stem cell transplantation in multiple myeloma. Panminerva Medica, 2021, 62, 220-224.	0.2	7
590	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). Blood, 2011, 118, 2756-2756.	0.6	7
591	The benefit of treatment with quizartinib and subsequent bridging to HSCT for FLT3-ITD(+) patients with AML.. Journal of Clinical Oncology, 2014, 32, 7093-7093.	0.8	7
592	Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, 7003-7003.	0.8	7
593	A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.. Journal of Clinical Oncology, 2017, 35, TPS7070-TPS7070.	0.8	7
594	Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome&quot;positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2018, 36, 7030-7030.	0.8	7

#	ARTICLE	IF	CITATIONS
595	Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up.. Journal of Clinical Oncology, 2020, 38, 7514-7514.	0.8	7
596	Novel Signalling Based Approach for Handling Linear and Non-Linear Impairments in Transparent Optical Networks. , 2009, , .		7
597	Mine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs. Blood, 2016, 128, 2808-2808.	0.6	7
598	Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 810387.	1.3	7
599	Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy. Haematologica, 1998, 83, 985-8.	1.7	7
600	Alu and translin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints. Haematologica, 2000, 85, 40-6.	1.7	7
601	Optimization of magnetic suspension devices by a surface current method. IEEE Transactions on Magnetics, 2001, 37, 2877-2880.	1.2	6
602	Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera. Journal of Clinical Pathology, 2006, 60, 581-582.	1.0	6
603	Analysis of Double Star Permanent Magnet Synchronous Generators by a General Decoupled d-q Model. , 2007, , .		6
604	Control strategy of a wind turbine drive by an integrated model. Wind Energy, 2009, 12, 33-49.	1.9	6
605	Low-level Bcrâ€“Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. Leukemia Research, 2011, 35, 1527-1529.	0.4	6
606	Single Step Multiple Genotyping by MALDI-TOF Mass Spectrometry, for Evaluation of Minor Histocompatibility Antigens in Patients Submitted to Allogeneic Stem Cell Transplantation from HLA-Matched Related and Unrelated Donor. Hematology Reports, 2017, 9, 7051.	0.3	6
607	A Two-Layer Network Solution for Reliable and Efficient Host-to-Host Transfer of Big Data. , 2018, , .		6
608	Occurrence and Origin of H<sub>2</sub>S from Volcanic Reservoirs in Niudong Area of the Santanghu Basin, NW China. Geofluids, 2019, 2019, 1-10.	0.3	6
609	Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?. British Journal of Haematology, 2020, 189, 335-338.	1.2	6
610	How I Manage Frontline Transplant-Ineligible Multiple Myeloma. Hematology Reports, 2020, 12, 8956.	0.3	6
611	ABVD vs BEACOPP escalated in advancedâ€“stage Hodgkinâ€™s lymphoma: Results from a multicenter European study. American Journal of Hematology, 2020, 95, 1030-1037.	2.0	6
612	Old and new generation proteasome inhibitors in multiple myeloma. Panminerva Medica, 2021, 62, 193-206.	0.2	6

#	ARTICLE	IF	CITATIONS
613	Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. <i>Biomedicines</i> , 2021, 9, 388.	1.4	6
614	Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684396.	1.3	6
615	Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue. <i>Biomedicines</i> , 2021, 9, 1242.	1.4	6
616	Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. <i>Cell Biology and Toxicology</i> , 2023, 39, 795-811.	2.4	6
617	Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035. <i>Blood</i> , 2008, 112, 2926-2926.	0.6	6
618	BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.. <i>Blood</i> , 2009, 114, 648-648.	0.6	6
619	Suppression of Bcr-Abl Expression in CML by A Panel of miRNAs.. <i>Blood</i> , 2009, 114, 854-854.	0.6	6
620	The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories. <i>Blood</i> , 2012, 120, 1399-1399.	0.6	6
621	Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03. <i>Blood</i> , 2013, 122, 508-508.	0.6	6
622	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. <i>Blood</i> , 2013, 122, 743-743.	0.6	6
623	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. <i>Blood</i> , 2014, 124, 738-738.	0.6	6
624	Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies. <i>Blood</i> , 2011, 118, 112-112.	0.6	6
625	Higher Expression of PALB2 Predict Poor Prognosis in AML Patients and Identifies Potential Targets of Synthetic Lethal Therapies. <i>Blood</i> , 2018, 132, 1507-1507.	0.6	6
626	Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one. <i>Haematologica</i> , 2002, 87, 688-94; discussion 694.	1.7	6
627	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 382.	0.6	5
628	Electromagnetic optimization of EMS-MAGLEV systems. <i>IEEE Transactions on Magnetics</i> , 1998, 34, 2090-2092.	1.2	5
629	The p210BCR-ABL tyrosine kinase of chronic myeloid leukemia causes resistance to radio-induced apoptotic death by inhibiting the proapoptotic BAX gene. <i>Leukemia</i> , 2004, 18, 370-372.	3.3	5
630	Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells. <i>Hematological Oncology</i> , 2008, 26, 159-166.	0.8	5

#	ARTICLE	IF	CITATIONS
631	Performance assessment of a single-phase PM synchronous motor for small fan appliances. , 2008, , .		5
632	Analysis of the air-gap asymmetry in axial-flux permanent magnet generators. , 2009, , .		5
633	Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration. Leukemia Research, 2010, 34, e246-e247.	0.4	5
634	Performance comparison of saturated tubular linear permanent magnet generators by simplified FEAs. , 2012, , .		5
635	A case report of acute myeloid leukemia and neurofibromatosis 1. Hematology Reports, 2013, 5, 8.	0.3	5
636	Complex chromosomal rearrangements leading to <i>MECOM</i> overexpression are recurrent in myeloid malignancies with various 3q abnormalities. Genes Chromosomes and Cancer, 2016, 55, 375-388.	1.5	5
637	Concurrent chromothripsis events in a case of TP53 depleted acute myeloid leukemia with myelodysplasia-related changes. Cancer Genetics, 2019, 237, 63-68.	0.2	5
638	Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis. Gastric Cancer, 2021, 24, 392-401.	2.7	5
639	Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. Panminerva Medica, 2021, 63, 1-6.	0.2	5
640	Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia. PLoS ONE, 2021, 16, e0247093.	1.1	5
641	A Novel 4-anilino-3-quinolinecarbonitrile Dual Src and Abl Kinase Inhibitor (SKI-606) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.. Blood, 2004, 104, 1991-1991.	0.6	5
642	Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.. Blood, 2006, 108, 208-208.	0.6	5
643	Interim 18f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2008, 112, 3607-3607.	0.6	5
644	Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia.. Blood, 2009, 114, 2080-2080.	0.6	5
645	Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study. Blood, 2010, 116, 432-432.	0.6	5
646	Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1 by the Italian Cooperative Group on Hcl. Blood, 2010, 116, 701-701.	0.6	5
647	Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression. Blood, 2010, 116, 885-885.	0.6	5
648	Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,. Blood, 2011, 118, 3770-3770.	0.6	5

#	ARTICLE	IF	CITATIONS
649	Cycling Toward Leukemia Stem Cell Elimination With a Selective Sonic Hedgehog Antagonist. Blood, 2011, 118, 3776-3776.	0.6	5
650	The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. Blood, 2012, 120, 1680-1680.	0.6	5
651	Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307. Blood, 2012, 120, 3784-3784.	0.6	5
652	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL). Blood, 2015, 126, 1493-1493.	0.6	5
653	Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline #7060. Journal of Clinical Oncology, 2008, 26, 7060-7060.	0.8	5
654	Assessment of the interlaboratory variability and robustness of JAK2 V617F mutation assays: A study involving a consortium of 19 Italian laboratories. Oncotarget, 2017, 8, 32608-32617.	0.8	5
655	Chibby 1: a new component of $\beta$ -catenin-signaling in chronic myeloid leukemia. Oncotarget, 2017, 8, 88244-88250.	0.8	5
656	Blinatumomab in Ph+ B-ALL: present and perspectives. Oncotarget, 2017, 8, 93309-93310.	0.8	5
657	Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia. Minerva Medica, 2020, 111, 386-394.	0.3	5
658	Tissue Microarray (TMA) Study in DLBC Lymphomas (DLBCL): Could the Extranodal Origin Affect the Prognostic Impact of the Analysis?.. Blood, 2006, 108, 2037-2037.	0.6	5
659	Fungal and Bacterial Infections in Acute Myeloid Leukemia Patients Treated with Induction Regimens Including Fludarabine: A Retrospective Analysis of 224 Cases.. Blood, 2007, 110, 4351-4351.	0.6	5
660	Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano. Blood, 2008, 112, 5016-5016.	0.6	5
661	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. Blood, 2011, 118, 786-786.	0.6	5
662	Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters. Frontiers in Immunology, 2021, 12, 804988.	2.2	5
663	Detection of clonality by heteroduplex analysis of amplified junctional region of T-cell receptor gamma in patients with T-cell acute lymphoblastic leukemias. Haematologica, 1997, 82, 161-5.	1.7	5
664	Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFbeta/MYH11 transcript. Haematologica, 2000, 85, 552-5.	1.7	5
665	Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis. Cancers, 2022, 14, 3231.	1.7	5
666	ecancermedalscience. Ecancermedalscience, 2014, 8, 429.	0.6	4

#	ARTICLE	IF	CITATIONS
667	Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders?. <i>European Journal of Haematology</i> , 2005, 74, 450-451.	1.1	4
668	Performance Assessment of a Wind PM Generator-Rectifier System by an Integrated FEM-Circuit Model. , 2007, , .		4
669	Resistance to Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Leukemias: Which Mutations Matter?. <i>Clinical Leukemia</i> , 2007, 1, 223-228.	0.2	4
670	PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 713-716.	1.1	4
671	Interferonâ€alpha may restore sensitivity to tyrosineâ€kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. <i>British Journal of Haematology</i> , 2009, 146, 227-230.	1.2	4
672	<i>AICDA</i> expression in <i>BCR/ABL1</i>-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. <i>British Journal of Haematology</i> , 2011, 152, 727-732.	1.2	4
673	Serum Total Tryptase Level Confirms Itself as a More Reliable Marker of Mast Cells Burden in Mast Cell Leukaemia (Aleukaemic Variant). <i>Case Reports in Hematology</i> , 2015, 2015, 1-4.	0.3	4
674	Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 24.	2.0	4
675	<scp>FGFR</scp>1 and <scp>KAT6A</scp> rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. <i>American Journal of Hematology</i> , 2016, 91, E14-6.	2.0	4
676	A WDM Network Controller With Real-Time Updates of the Physical Layer Abstraction. <i>Journal of Lightwave Technology</i> , 2019, 37, 4073-4080.	2.7	4
677	Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9724.	1.8	4
678	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2020, 105, 47-55.	1.1	4
679	Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 395.	1.0	4
680	Nextâ€generation sequencing improves BCRâ€ABL1 mutation detection in Philadelphia chromosomeâ€positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 271-279.	1.2	4
681	Old and new generation immunomodulatory drugs in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 207-219.	0.2	4
682	Concentrationâ€QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 513-523.	1.1	4
683	BCMA-targeting approaches for treatment of multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 28-36.	0.2	4
684	Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient. <i>Frontiers in Medicine</i> , 2021, 8, 689895.	1.2	4

#	ARTICLE	IF	CITATIONS
685	Molecular Heterogeneity of the FIP1L1-PDGFR $\alpha$ Fusion Gene in Chronic Eosinophilic Leukemia (CEL) and Systemic Mastocytosis with Eosinophilia (SME): A Study of 43 Cases.. Blood, 2004, 104, 2428-2428.	0.6	4
686	A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.. Blood, 2004, 104, 4687-4687.	0.6	4
687	Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML.. Blood, 2005, 106, 435-435.	0.6	4
688	Gene Expression Profiling (GEP) of Myeloma (MM) Cells To Predict Attainment (near) Complete Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed MM.. Blood, 2006, 108, 245-245.	0.6	4
689	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. Blood, 2007, 110, 26-26.	0.6	4
690	Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).. Blood, 2007, 110, 4499-4499.	0.6	4
691	Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score. Blood, 2008, 112, 3190-3190.	0.6	4
692	Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party. Blood, 2008, 112, 722-722.	0.6	4
693	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. Blood, 2012, 120, 2601-2601.	0.6	4
694	Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist. Blood, 2016, 128, 2843-2843.	0.6	4
695	Randomized phase III study of high-dose sequential chemotherapy (CT) supported by peripheral blood progenitor cells (PBPC) for the treatment of small cell lung cancer (SCLC): Results of the EBMT Random-ICE trial. Journal of Clinical Oncology, 2006, 24, 7064-7064.	0.8	4
696	Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy.. Journal of Clinical Oncology, 2016, 34, 7028-7028.	0.8	4
697	New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. Minerva Medica, 2020, 111, 478-490.	0.3	4
698	Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Oncology Reports, 2020, 44, 1561-1573.	1.2	4
699	Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. Blood, 2005, 106, 1098-1098.	0.6	4
700	Rituximab Reduces Anti-UL94 and Anti-NAG-2 Antibodies Titer and Is Effective against Skin-Chronic Graft Versus Host Disease Resembling Scleroderma.. Blood, 2009, 114, 4654-4654.	0.6	4
701	Non-Myeloablative Haploidentical Transplantation of Unmanipulated, G-CSF Mobilized Peripheral Blood Stem Cells with High Dose Post-Transplant Cyclophosphamide: Fast Engraftment, No Evidence of Graft Rejection and Low Incidence of Graft-Versus-Host-Disease. Blood, 2014, 124, 3887-3887.	0.6	4
702	Amplification of third-Complementary-Determining-Region (CDR-III) of heavy chain immunoglobulin gene (IgH) in one hundred adult acute leukemias. Leukemia and Lymphoma, 1997, 26, 131-139.	0.6	3



#	ARTICLE	IF	CITATIONS
703	Mosaic tumour blood vessels and high-dose chemotherapy for breast cancer. <i>Lancet Oncology</i> , The, 2001, 2, 595.	5.1	3
704	No Preferential Sensitivity of t(8;21) Acute Myeloid Leukemias to Cytosine Arabinoside in Vitro: Is Intensity of Therapy or High Dose Ara-C Crucial for Response?. <i>Leukemia and Lymphoma</i> , 2004, 45, 1361-1364.	0.6	3
705	MK-0457: a light at the end of the tunnel?. <i>Blood</i> , 2007, 109, 396-397.	0.6	3
706	Acute promyelocytic leukemia with amplification of PML-RAR $\alpha$ rearrangement: Clinical implications. <i>Leukemia Research</i> , 2008, 32, 1941-1943.	0.4	3
707	IPO-trimethylation of histone H3-lysine9 associated with P210 BCR-ABL tyrosine kinase of chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2008, 141, 899-902.	1.2	3
708	Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?. <i>Hematology Reports</i> , 2009, 1, 1.	0.3	3
709	Toward deployment of signalling-based approach for linear and non-linear impairment-aware lightpath setup in transparent optical networks. <i>IEEE Communications Letters</i> , 2010, 14, 254-256.	2.5	3
710	Imputation reliability on DNA biallelic markers for drug metabolism studies. <i>BMC Bioinformatics</i> , 2012, 13, S7.	1.2	3
711	Posterior Reversible Encephalopathy Syndrome in a B-Cell Acute Lymphoblastic Leukemia Young Adult Patient Treated with a Pediatric-like Chemotherapeutic Schedule. <i>Hematology Reports</i> , 2014, 6, 5565.	0.3	3
712	The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. <i>American Journal of Hematology</i> , 2015, 90, 56-61.	2.0	3
713	Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2479-2486.	0.9	3
714	Chromothripsis in acute myeloid leukemia: Biological features and impact on survival. <i>Leukemia</i> , 2017, , .	3.3	3
715	Demonstration of an SDN orchestrator for both flow provisioning and fault handling in an Ethernet-over-WDM Network. , 2017, , .		3
716	Texture analysis in <sup>177</sup> Lu SPECT phantom images: Statistical assessment of uniformity requirements using texture features. <i>PLoS ONE</i> , 2019, 14, e0218814.	1.1	3
717	Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S217-S218.	0.2	3
718	Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	3
719	Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents. <i>Molecules</i> , 2021, 26, 683.	1.7	3
720	Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. <i>Leukemia Research</i> , 2021, 101, 106497.	0.4	3

#	ARTICLE	IF	CITATIONS
721	The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia. Expert Opinion on Drug Safety, 2021, 20, 791-799.	1.0	3
722	Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway. Blood Cancer Journal, 2021, 11, 7.	2.8	3
723	Abstract 5552: Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408. , 2014, , .		3
724	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. Blood, 2018, 132, 789-789.	0.6	3
725	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. Blood, 2018, 132, 458-458.	0.6	3
726	Expression of the Human Concentrative Nucleotide Transporter (hCNT1) Gene Correlates with Clinical Response in Patients Affected by Waldenström's Macroglobulinemia (WM), Undergoing a Combination Treatment with Cladribine (2-CdA) and Rituximab.. Blood, 2007, 110, 1357-1357.	0.6	3
727	High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.. Blood, 2007, 110, 1890-1890.	0.6	3
728	The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.. Blood, 2008, 112, 1106-1106.	0.6	3
729	The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. Blood, 2009, 114, 2192-2192.	0.6	3
730	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. Blood, 2009, 114, 860-860.	0.6	3
731	PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. Blood, 2011, 118, 1429-1429.	0.6	3
732	Gas1 and Kif27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. Blood, 2011, 118, 1535-1535.	0.6	3
733	In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL). Blood, 2012, 120, 1496-1496.	0.6	3
734	Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study. Blood, 2013, 122, 3824-3824.	0.6	3
735	Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome. Blood, 2014, 124, 484-484.	0.6	3
736	The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway. Blood, 2015, 126, 1276-1276.	0.6	3
737	Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform. Blood, 2016, 128, 1675-1675.	0.6	3
738	Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial.. Journal of Clinical Oncology, 2016, 34, 7029-7029.	0.8	3

#	ARTICLE	IF	CITATIONS
739	A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia.. Journal of Clinical Oncology, 2016, 34, TPS7072-TPS7072.	0.8	3
740	Low pegfilgrastim serum concentration at 11th day allows chemotherapy intensification in advanced Hodgkin's disease patients. Journal of Clinical Oncology, 2005, 23, 6699-6699.	0.8	3
741	Identification of Genes Sustaining Bcr-Abl Oncogenic Signalling and CML Progression through a Genetic Tool Based on Human Bcr-Abl Transgenic Drosophila Melanogaster.. Blood, 2008, 112, 1091-1091.	0.6	3
742	ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. Blood Advances, 2022, 6, 2510-2516.	2.5	3
743	Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Cancers, 2021, 13, 5607.	1.7	3
744	Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia. Cancer Medicine, 2022, 11, 618-629.	1.3	3
745	Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment. Hematological Oncology, 2022, 40, 734-742.	0.8	3
746	«Fingerprinting» of HLA-DQA by polymerase chain reaction and heteroduplex analysis. Molecular and Cellular Probes, 1996, 10, 123-127.	0.9	2
747	Optimization of the magnetic configuration in EMS-MAGLEV systems. International Journal of Applied Electromagnetics and Mechanics, 1999, 10, 1-19.	0.3	2
748	Quantitative Evaluation of BCR-ABL Amount of Transcript Post Mobilization with G-CSF of Peripheral Blood Stem Cells from Chronic Myeloid Leukemia Patients in Cytogenetic Response. Leukemia and Lymphoma, 2000, 39, 113-120.	0.6	2
749	Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia. European Journal of Haematology, 2004, 72, 302-303.	1.1	2
750	Chlorambucil + rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis. Leukemia and Lymphoma, 2007, 48, 437-438.	0.6	2
751	Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. Hematology, 2008, 13, 1-12.	0.7	2
752	Towards deployment of signalling based approaches for impairment aware lightpath setup in transparent WDM optical networks. , 2008, , .		2
753	A competency based educational programme for research nurses: An Italian experience. Ecanermedicalscience, 2009, 3, 134.	0.6	2
754	Secondary haematological malignancies after radioimmunotherapy. Annals of Hematology, 2012, 91, 969-969.	0.8	2
755	Treatment for patients with indolent and mantle cell lymphoma. Lancet, The, 2013, 382, 1094.	6.3	2
756	R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma. Transfusion and Apheresis Science, 2014, 50, 411-414.	0.5	2

#	ARTICLE	IF	CITATIONS
757	Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: the QuANTUM-R study. <i>Annals of Oncology</i> , 2016, 27, vi327.	0.6	2
758	Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia. <i>Tumor Biology</i> , 2016, 37, 217-225.	0.8	2
759	Orchestration of reliable three-layer networks. , 2017, , .		2
760	The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report. <i>BMC Cancer</i> , 2017, 17, 523.	1.1	2
761	Combining Electronic Layer Protection and Pre-Planned Optical Restoration for Improved and Resource-Efficient Reliability. , 2018, , .		2
762	Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results. <i>Annals of Oncology</i> , 2019, 30, vi81.	0.6	2
763	Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) â€“ Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S221-S222.	0.2	2
764	How We Manage Smoldering Multiple Myeloma. <i>Hematology Reports</i> , 2020, 12, 8951.	0.3	2
765	Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1629-1641.	1.0	2
766	Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis. <i>Hematological Oncology</i> , 2020, 38, 201-203.	0.8	2
767	Exposureâ€“response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 927-935.	1.3	2
768	Abstract 906:Gas1andKif27genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients. , 2012, , .		2
769	Quantitative Assessment of Indoleamine 2,3-Dioxygenase (IDO) Expression at Diagnosis Predicts Clinical Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 5261-5261.	0.6	2
770	A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on Chronic Myeloid Leukaemia (CML) Ph+ Cells Resistant to Imatinib.. <i>Blood</i> , 2005, 106, 2004-2004.	0.6	2
771	Efficacy of 90Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkinâ€™s Lymphoma.. <i>Blood</i> , 2006, 108, 2771-2771.	0.6	2
772	Red Marrow Dosimetry and Stem Cell Reinfusion in High Dose 90Y - Ibritumomab Tiuxetan.. <i>Blood</i> , 2008, 112, 2187-2187.	0.6	2
773	Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.. <i>Blood</i> , 2009, 114, 1130-1130.	0.6	2
774	Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT). <i>Blood</i> , 2010, 116, 1973-1973.	0.6	2

#	ARTICLE	IF	CITATIONS
775	The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.. Blood, 2010, 116, 3410-3410.	0.6	2
776	Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. Blood, 2010, 116, 3413-3413.	0.6	2
777	Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome-Positive Leukemias.. Blood, 2010, 116, 3434-3434.	0.6	2
778	Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells. Blood, 2011, 118, 2596-2596.	0.6	2
779	Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors. Blood, 2011, 118, 2760-2760.	0.6	2
780	HIF 1 Alpha: A Suitable Target for Multiple Myeloma. Blood, 2011, 118, 2901-2901.	0.6	2
781	Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies. Blood, 2012, 120, 284-284.	0.6	2
782	The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients. Blood, 2012, 120, 4876-4876.	0.6	2
783	Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications. Blood, 2012, 120, 692-692.	0.6	2
784	PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients. Blood, 2013, 122, 1936-1936.	0.6	2
785	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. Blood, 2013, 122, 258-258.	0.6	2
786	Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy. Blood, 2013, 122, 380-380.	0.6	2
787	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. Blood, 2013, 122, 770-770.	0.6	2
788	Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harboring FLT3 Mutations in AML Patients. Blood, 2014, 124, 1040-1040.	0.6	2
789	Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients. Blood, 2014, 124, 1809-1809.	0.6	2
790	Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. Blood, 2014, 124, 1881-1881.	0.6	2
791	Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients. Blood, 2015, 126, 1606-1606.	0.6	2
792	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. Blood, 2015, 126, 2792-2792.	0.6	2

#	ARTICLE	IF	CITATIONS
793	RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3627-3627.	0.6	2
794	Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. <i>Blood</i> , 2015, 126, 4085-4085.	0.6	2
795	High dose 90Yttrium ibritumomab tiuxetan with PBSC support in refractory-resistant NHL patients: Preliminary results of a phase I/II study. <i>Journal of Clinical Oncology</i> , 2006, 24, 7587-7587.	0.8	2
796	Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2010, 28, 8065-8065.	0.8	2
797	Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7038-7038.	0.8	2
798	Development of a Genetic Tool Based on BCR-ABL Transgenic <i>Drosophila Melanogaster</i> for Identification of Genes Involved in CML Progression and Drug Testing.. <i>Blood</i> , 2007, 110, 468-468.	0.6	2
799	Phase I/II Study of Tipifarnib and Bortezomib in the Treatment of Poor Risk Adult Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 2982-2982.	0.6	2
800	PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.. <i>Blood</i> , 2009, 114, 12-12.	0.6	2
801	BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2167-2167.	0.6	2
802	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. <i>Blood</i> , 2010, 116, 1230-1230.	0.6	2
803	Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107). <i>Blood</i> , 2010, 116, 510-510.	0.6	2
804	Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. <i>Blood</i> , 2011, 118, 4635-4635.	0.6	2
805	Potential Pathogenetic Role of <i>Achromobacter</i> ( <i>Alcaligenes</i> ) <i>Xylosoxidans</i> in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. <i>Blood</i> , 2011, 118, 880-880.	0.6	2
806	Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.. <i>Blood</i> , 2012, 120, 2797-2797.	0.6	2
807	Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study. <i>Blood</i> , 2016, 128, 2288-2288.	0.6	2
808	Unravel Inter-Tumor and Intra-Tumor Heterogeneity of Digitally Sorted Single Hodgkin and Reed Sternberg Cells Using Genome-Wide Copy Number Profiling. <i>Blood</i> , 2018, 132, 1568-1568.	0.6	2
809	Mitoxantrone, Etoposide and Cytarabine (MEC) Can Induce Deep Complete Remission and Is an Effective Bridge Therapy to Allotransplantation (SCT) in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , 2018, 132, 4036-4036.	0.6	2
810	Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use. <i>Minerva Medica</i> , 2020, 111, 443-454.	0.3	2

#	ARTICLE	IF	CITATIONS
811	Acute leukemias in 2020: state of the art. <i>Minerva Medica</i> , 2020, 111, 384-385.	0.3	2
812	Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 2352.	1.7	2
813	Performance improvement of low-rate single-phase alternators. , 0, , .		1
814	Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2004, 151, 85-86.	1.0	1
815	Rating of the power components in series-hybrid buses with different supply control strategies. , 0, , .		1
816	May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML?. <i>Leukemia Research</i> , 2007, 31, 269-271.	0.4	1
817	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. <i>Leukemia Research</i> , 2008, 32, 1628-1632.	0.4	1
818	Efficacy of 90Y Ibritumomab-Tiuxetan Treatment in a Case of Resistant Gastric Malt Non Hodgkin's Lymphoma. <i>Ecancermedalscience</i> , 2008, 2, 79.	0.6	1
819	Hematologic Toxicity and Double Autografting of Stem Cells After Myeloablative Activities of Yttrium-90â€“Ibritumomab Tiuxetan. <i>Journal of Clinical Oncology</i> , 2009, 27, 1145-1146.	0.8	1
820	Communication skills and raising awareness in clinical practice: An Italian experience. <i>Ecancermedalscience</i> , 2009, 3, 135.	0.6	1
821	A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia. <i>Hematology Reports</i> , 2012, 4, e27.	0.3	1
822	Best Effort Multi-Rate Optical Networks. , 2015, , .		1
823	WA-Method-TLV improves reliability of GMPLS WDM networks against multiple link failures. , 2015, , .		1
824	Optimization of an Electrodynamical Linear Actuator for Biometric Applications. <i>IEEE Transactions on Magnetics</i> , 2015, 51, 1-6.	1.2	1
825	Effects of multi-link failures on low priority traffic in MPLS-TE networks. , 2015, , .		1
826	Optical layer-driven network restoration and redesign for improved fast reroute reliability. , 2016, , .		1
827	Spectrum assignment constraints for improved OSNR in optical networks with dynamic traffic. , 2017, , .		1
828	An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia. <i>Anti-Cancer Drugs</i> , 2020, 31, 67-72.	0.7	1

#	ARTICLE	IF	CITATIONS
829	Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?. <i>Medicine (United States)</i> , 2020, 99, e21440.	0.4	1
830	Current and future perspectives of maintenance therapy in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 225-233.	0.2	1
831	Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 13-20.	0.2	1
832	Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma. <i>Supportive Care in Cancer</i> , 2021, 29, 6973-6980.	1.0	1
833	Abstract 251: Disabled gene is involved in CML progression and its expression level at diagnosis can predict major molecular response (MMR) to imatinib therapy. , 2010, , .		1
834	Abstract 311: Loss of the tumor suppressor genes CDKN2A/ARF impairs prognosis in adult BCR-ABL1 positive acute lymphoblastic leukemia (ALL). , 2011, , .		1
835	Abstract 746: PKC412 (Midostaurin) is safe and highly effective in systemic mastocytosis patients: Follow up of a single-center Italian compassionate use. , 2014, , .		1
836	Abstract 2651: Deep hypoxia and the genomic background cooperate to shape the metabolic profile of acute myeloid leukemia cells. , 2019, , .		1
837	Abstract 5279: Metabolic profiling defines a new characterization of acute myeloid leukemia and identifies NPM1-mutated cases as a distinct subgroup. , 2019, , .		1
838	Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03. <i>Blood</i> , 2018, 132, 1601-1601.	0.6	1
839	Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study. <i>Blood</i> , 2018, 132, 4078-4078.	0.6	1
840	ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study. <i>Blood</i> , 2019, 134, 1565-1565.	0.6	1
841	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFR $\alpha$ Rearrangement treated with Imatinib.. <i>Blood</i> , 2004, 104, 1507-1507.	0.6	1
842	Better Molecular Response (MR) to Imatinib (IM) in Early Chronic Phase (CP) Versus Late CP Chronic Myeloid Leukemia (CML) Patients (pts) in Complete Cytogenetic Response (CCR): A Comparison at 24 Months of 2 Clinical Trials of the GIMEMA Working Party on CML on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. <i>Blood</i> , 2005, 106, 1096-1096.	0.6	1
843	Deletions of the Derivative Chromosome 9 Do Not Influence Response to Imatinib of Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis).. <i>Blood</i> , 2006, 108, 2112-2112.	0.6	1
844	Valganciclovir Is Safe and Effective as Pre-Emptive Treatment for CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 5300-5300.	0.6	1
845	EphA3 Kinase Is Constitutively Activated in Chronic Myeloid Leukaemia during Progression to Accelerated and Blast Crisis and It Could Represent a New Molecular Target.. <i>Blood</i> , 2008, 112, 1092-1092.	0.6	1
846	The Oncogenic Kinase Bcr-Abl Directly Regulates Splicing of BclX through a Quaternary Complex Coordinated by Nck-Beta and Sam-68 Adapter Proteins.. <i>Blood</i> , 2009, 114, 2171-2171.	0.6	1



#	ARTICLE	IF	CITATIONS
847	High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.. Blood, 2009, 114, 2176-2176.	0.6	1
848	Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma).. Blood, 2009, 114, 3939-3939.	0.6	1
849	Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment. Blood, 2010, 116, 233-233.	0.6	1
850	Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study. Blood, 2010, 116, 4029-4029.	0.6	1
851	BCL2 Splice Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor. Blood, 2011, 118, 2735-2735.	0.6	1
852	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. Blood, 2011, 118, 453-453.	0.6	1
853	The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood, 2011, 118, 76-76.	0.6	1
854	Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia.. Blood, 2012, 120, 2522-2522.	0.6	1
855	Prognostic Impact Of Serum Free Light Chain (sFLC) Assay In Newly Diagnosed Multiple Myeloma (MM) Treated With Bortezomib. Blood, 2013, 122, 1859-1859.	0.6	1
856	Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity. Blood, 2015, 126, 821-821.	0.6	1
857	Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50. Blood, 2016, 128, 1702-1702.	0.6	1
858	Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. Blood, 2016, 128, 3068-3068.	0.6	1
859	A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.. Journal of Clinical Oncology, 2014, 32, TPS3116-TPS3116.	0.8	1
860	"ARMY": First-in-human study of the humanized, defucosylated monoclonal antibody (mAb) MEN1112/OBT357 targeting CD157 antigen, in relapsed or refractory (R/R) acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2015, 33, TPS3100-TPS3100.	0.8	1
861	Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.. Journal of Clinical Oncology, 2018, 36, 7029-7029.	0.8	1
862	Gene Expression Profile in the CML Cell Line K562 Treated with SKI-606, a Dual Inhibitor of Src/Abl Kinase.. Blood, 2005, 106, 4870-4870.	0.6	1
863	Efficacy and Tolerability of Liposomal Cytosine Arabinoside (DepoCyte®) for the Treatment of Lymphomatous and Leukemic Meningitis.. Blood, 2006, 108, 4674-4674.	0.6	1
864	CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients.. Blood, 2006, 108, 371-371.	0.6	1

#	ARTICLE	IF	CITATIONS
865	The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL. Blood, 2007, 110, 3344-3344.	0.6	1
866	Rituximab and 2-Cda Activity in CLL/SLL Patients: An Update of Pharmacogenomic and Clinical Results. Blood, 2008, 112, 3171-3171.	0.6	1
867	Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma. Blood, 2008, 112, 3063-3063.	0.6	1
868	Imatinib Induced Re-Activation of FoxO3 Transcription Factor in CML Is Responsible for the Induction of a Quiescent Status of CD34 Leukaemic Progenitor Cells.. Blood, 2008, 112, 1090-1090.	0.6	1
869	5-Azacytidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter Trial. Blood, 2008, 112, 3648-3648.	0.6	1
870	Aberrant Splicing of the SLP65 SH2 Domain Enables Pre-B Cell Transformation and Compromises the Leukemia-Suppressive Function of the Pre-B Cell Receptor. Blood, 2008, 112, 294-294.	0.6	1
871	The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug-Resistance in Chronic Myeloid Leukemia.. Blood, 2009, 114, 3274-3274.	0.6	1
872	RASGRP1/APTX Ratio Strongly Correlates with Clinical Response and Survival in AML Patients Treated with Tipifarnib-Bortezomib Combination.. Blood, 2009, 114, 1028-1028.	0.6	1
873	Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression.. Blood, 2009, 114, 3470-3470.	0.6	1
874	Abstract 2143: High-Resolution Molecular Karyotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Identifies Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes. , 2010, , .		1
875	Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen. Blood, 2010, 116, 4335-4335.	0.6	1
876	The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 2732-2732.	0.6	1
877	Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation. Blood, 2012, 120, 1396-1396.	0.6	1
878	Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib. Blood, 2012, 120, 3739-3739.	0.6	1
879	Genomic Analysis Of Notch Mutations In a Case Of Alagille Syndrome With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 4992-4992.	0.6	1
880	Novel Chimeric Transcripts Involving PAX5 in B-Cell Precursor ALL. Blood, 2013, 122, 1367-1367.	0.6	1
881	Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing. Blood, 2014, 124, 1028-1028.	0.6	1
882	FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia. Blood, 2014, 124, 3125-3125.	0.6	1

#	ARTICLE	IF	CITATIONS
883	Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells. <i>Blood</i> , 2014, 124, 624-624.	0.6	1
884	Genomic Analysis of Notch Mutations in a Case of Alagille Syndrome with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 5338-5338.	0.6	1
885	Abstract 90: A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia. <i>Cancer Research</i> , 2016, 76, 90-90.	0.4	1
886	Abstract 2723: The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia. , 2016, , .		1
887	A Branching Evolution Model at Relapse Characterizes Multiple Myeloma Patients Who Responded to up-Front Combination Therapy Including New Drugs. <i>Blood</i> , 2016, 128, 2080-2080.	0.6	1
888	Alterations in Pathways Regulating Phosphatidyl Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 1679-1679.	0.6	1
889	The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. <i>Blood</i> , 2016, 128, 3136-3136.	0.6	1
890	Abstract 1229: Clonal hematopoiesis of indeterminate potential (CHIP), centenarians and age-related cardiovascular risk: Is TET2 the culprit. , 2018, , .		1
891	Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL). <i>Blood</i> , 2018, 132, 1418-1418.	0.6	1
892	MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment. <i>Blood</i> , 2018, 132, 1779-1779.	0.6	1
893	Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18313-e18313.	0.8	1
894	Abstract 3889: Population pharmacokinetic/pharmacodynamic evaluation of the effect of glasdegib exposure on cardiac repolarization (QT interval) in cancer patients. , 2019, , .		1
895	Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 1343-1343.	0.6	1
896	An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e31321.	2.1	1
897	Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells. <i>Cancers</i> , 2022, 14, 738.	1.7	1
898	Carboplatin (CBDCA) and paclitaxel (TAX) as induction chemotherapy in stage IIIA-IIIIB in non small cell lung cancer (NSCLC). <i>European Journal of Cancer</i> , 1999, 35, S264.	1.3	0
899	Screening of Bcr-Abl Transcripts in Philadelphia Negative Essential Thrombocythemia. <i>Leukemia and Lymphoma</i> , 2000, 39, 339-341.	0.6	0
900	Reply to Tattevin and Camus. <i>Clinical Infectious Diseases</i> , 2006, 42, 1814-1815.	2.9	0

#	ARTICLE	IF	CITATIONS
901	Response to Letter Regarding Article, "Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition". <i>Circulation</i> , 2007, 115, .	1.6	0
902	Atypical Chronic Myeloproliferative Disorders: Genes and Imatinib-Sensitive Targets. <i>Seminars in Hematology</i> , 2007, 44, S1-S3.	1.8	0
903	C033 Quantification of phosphoinositidephospholipase C (PI-PLC) beta 1 gene promoter methylation predicts the responsiveness to azacitidine in myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, S51.	0.4	0
904	9207 Efficacy of 90Yttrium-ibritumomab tiuxetan in extranodal marginal-zone lymphoma. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 562.	2.2	0
905	Is there a role for 'modified VAD' in the treatment of multiple myeloma?. <i>Ecancermedicalsecience</i> , 2010, 3, 136.	0.6	0
906	Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. <i>Leukemia</i> , 2010, , .	3.3	0
907	A novel framework for chimeric transcript detection based on accurate gene fusion model. , 2011, , .		0
908	NICER: A distributed dynamic shared-backup path-allocation procedure for transmission-impaired WDM optical networks. , 2012, , .		0
909	Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: A case report. <i>Transfusion and Apheresis Science</i> , 2013, 49, 205-207.	0.5	0
910	Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> . 2013;121(26):5138-5144.. <i>Blood</i> , 2014, 123, 2902-2902.	0.6	0
911	Interferon in CML: back to the past, or towards the future?. <i>Lancet Haematology,the</i> , 2015, 2, e8-e9.	2.2	0
912	NETWORK APPROACHES FOR ANALYSIS AND MODELING OF THE HUMAN METABOLISM. <i>Journal of Mechanics in Medicine and Biology</i> , 2015, 15, 1540026.	0.3	0
913	Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia. <i>Lancet Haematology,the</i> , 2016, 3, e554-e555.	2.2	0
914	RALE051: a novel established cell line of sporadic Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1252-1255.	0.6	0
915	Tyrosine Kinase Inhibitors (TKI) in Relapsed/Refractory (RR) Patients with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Confer Better Survival than Chemotherapy, Due to a Better Safety Profile. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S200.	0.2	0
916	Age, Disease Status before Blinatumomab, MRD Negativity Obtainment, and Bridge to Transplant Influence Outcome in Patients with B-ALL: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S181-S182.	0.2	0
917	Ponatinib vs Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) ALL: PhALLCON Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S194.	0.2	0
918	Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e358.	0.2	0

#	ARTICLE	IF	CITATIONS
919	Identification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome. International Journal of Colorectal Disease, 2019, 34, 1999-2002.	1.0	0
920	Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in Novel Agents' Era. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e359-e360.	0.2	0
921	PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. HemaSphere, 2019, 3, 37-38.		0
922	Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e358-e359.	0.2	0
923	How I manage frontline transplant-eligible multiple myeloma in Italy. Hematology Reports, 2020, 12, 8954.	0.3	0
924	Multiple myeloma in 2020: state of the art. Panminerva Medica, 2021, 62, 191-192.	0.2	0
925	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.. Blood, 2004, 104, 4655-4655.	0.6	0
926	Imatinib in the Treatment of CML Patients ≥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.. Blood, 2004, 104, 2935-2935.	0.6	0
927	Prognostic Value of BCL2 Determination in Follicular NHL Patients Treated with Alkylating Containing Regimen Alone or in Combination with Rituximab.. Blood, 2004, 104, 4629-4629.	0.6	0
928	Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia Patients By GIMEMA Working Party on CML.. Blood, 2004, 104, 4672-4672.	0.6	0
929	Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. Blood, 2005, 106, 1100-1100.	0.6	0
930	Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation in Renal Cell Carcinoma: The EIO Experience.. Blood, 2005, 106, 5424-5424.	0.6	0
931	Antiproliferative Effects of Tyrosine Kinase (STI 571) and Farnesyl Transferase Inhibitors (R115777 and) Tj ETQq1 1 0,784314,rgBT /O	0,6	0
932	SU11657, a FLT3-Targeted Tyrosine Kinase, Has Pro-Apoptotic Activity on Leukemia Cells In Vitro.. Blood, 2005, 106, 2797-2797.	0.6	0
933	Tumor Control Achieved Despite Loss of Chimaerism in Renal Cell Carcinoma (RCC) Following Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): A Case Report.. Blood, 2005, 106, 5401-5401.	0.6	0
934	High Dose Chemotherapy with Autologous Stem Cell Support Is Effective in Resistant and Refractory Hodgkin Lymphoma. A Single Center Analysis.. Blood, 2005, 106, 5506-5506.	0.6	0
935	Comparison of Cytogenetics and Interphase Fluorescence In Situ Hybridization in Newly Diagnosed Ph+ Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate. A Study by the GIMEMA Working Party on CML. On Behalf of GWP on CML.. Blood, 2005, 106, 4857-4857.	0.6	0
936	Graft-Versus-Lymphoma Effect in Hodgkin's Disease: A Possible Role in Maintaining a Disease Control.. Blood, 2005, 106, 5423-5423.	0.6	0

#	ARTICLE	IF	CITATIONS
937	Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.. Blood, 2006, 108, 2156-2156.	0.6	0
938	Acute Myeloid Leukemia-Derived Dendritic Cells Express the Immunoregulatory Enzyme Indoleamine 2,3-dioxygenase.. Blood, 2006, 108, 1899-1899.	0.6	0
939	A Study of the Binding Mode and the In Vitro Activity of the Protein Tyrosine Kinase Inhibitor SKI-606 in the BCR-ABL Positive Cells.. Blood, 2006, 108, 2335-2335.	0.6	0
940	Direct and Coordinate Regulation of Multidrug Resistance Genes by the c-Myc Oncoprotein.. Blood, 2006, 108, 2594-2594.	0.6	0
941	FLT-3 Activity and Its Response to Drugs Can Be Determined in AML Blast Cells by FLT-3 Phosphorylation Status Using Flow Cytometry.. Blood, 2006, 108, 2308-2308.	0.6	0
942	NPM Mutations and Not FLT3 Mutations Are a Potential Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia.. Blood, 2006, 108, 2016-2016.	0.6	0
943	Lymphoid Subpopulations and Safety Profile in Untreated-Follicular Lymphoma Receiving Rituximab Monotherapy as Induction and Maintenance Therapy.. Blood, 2006, 108, 4705-4705.	0.6	0
944	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. Blood, 2006, 108, 4805-4805.	0.6	0
945	Prevalence and Prognostic Significance of FLT3 Mutations in Acute Myeloid Leukemia: Association of ITDs with Poor Outcome in Patients with Normal Cytogenetics.. Blood, 2006, 108, 2017-2017.	0.6	0
946	Phase II trial of cladribine (2-CdA) and rituximab in patients with CLL and SLL: Preliminary report of a single institution. Journal of Clinical Oncology, 2007, 25, 7093-7093.	0.8	0
947	Five-year follow-up results of imatinib 400 mg in late chronic phase chronic myeloid leukemia (CML) patients. Journal of Clinical Oncology, 2007, 25, 7041-7041.	0.8	0
948	Variable but Consistent Pattern of Meningioma 1 Gene (MN1) Expression in Different Genetic Subsets of Acute Myelogenous Leukaemia and Its Potential Use as Marker for Minimal Residual Disease Detection.. Blood, 2007, 110, 3494-3494.	0.6	0
949	Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan.. Blood, 2007, 110, 5116-5116.	0.6	0
950	IELSG Phase II Studies of Bortezomib in Malt Lymphomas.. Blood, 2007, 110, 2580-2580.	0.6	0
951	Phase I-II Trial of Adoptive Immunotherapy with Haploidentical KIR Ligand-Mismatched Natural Killer Cells in High Risk Acute Myeloblastic Leukemia Patients.. Blood, 2007, 110, 2857-2857.	0.6	0
952	Down-Modulation of Shp1 and Hsp70 Provides a Survival Advantage to the Ph+ Cells of CML Patients Additive to That Related to the Oncogenic BCR/ABL Protein and May Account for Resistance to Ima Treatment.. Blood, 2007, 110, 1014-1014.	0.6	0
953	Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin's Lymphoma (HL): A Single Centre Experience.. Blood, 2007, 110, 4463-4463.	0.6	0
954	The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.. Blood, 2007, 110, 3355-3355.	0.6	0

#	ARTICLE	IF	CITATIONS
955	FoxO Transcription Factor Is Delocalized in CML Patients by Bcr-Abl Induced PI3K/AKT Activation and IKK Pathway and Can Be Reactivated by Imatinib Treatment.. Blood, 2007, 110, 1010-1010.	0.6	0
956	The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors.. Blood, 2007, 110, 722-722.	0.6	0
957	Genome-wide profiling of DNA copy number abnormalities in adult acute myeloid leukemia (AML) using high density single nucleotide polymorphism array. Journal of Clinical Oncology, 2008, 26, 7023-7023.	0.8	0
958	Equivalent Efficacy and Lower Toxicity of Subcutaneous Cladribine at Reduced Doses (Five versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Italian Cooperative Group on Hcl. Blood, 2008, 112, 3174-3174.	0.6	0
959	The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study). Blood, 2008, 112, 3608-3608.	0.6	0
960	Two Novel WT-1 Derived Peptides Induce CD4+ peptide-specific T Cell Proliferation in Patients with Myelodysplastic Syndrome (MDS). Blood, 2008, 112, 5432-5432.	0.6	0
961	Identification and Molecular Characterization of Two Recurrent Genomic Deletions (Type A and Type) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Behalf of the CIMEMA ALL Working Party. Blood, 2008, 112, 428-428.	0.6	0
962	Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1. Blood, 2008, 112, 15-15.	0.6	0
963	The Pre-B Cell Receptor Suppresses Leukemogenesis by Censoring MYC Expression.. Blood, 2008, 112, 1918-1918.	0.6	0
964	Primary Female Genital Lymphoma: Prognostic and Therapeutic Considerations. Blood, 2008, 112, 4941-4941.	0.6	0
965	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. Blood, 2008, 112, 478-478.	0.6	0
966	Identification of the Involvement of the Tyrosine Kinase C-Ros in the Pathogenesis of Chronic Myelomonocytic Leukemia (CMML). Blood, 2008, 112, 687-687.	0.6	0
967	Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML patients Younger Than 65 Years. Report of a Multicentric Trial. Blood, 2008, 112, 3998-3998.	0.6	0
968	Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.. Blood, 2008, 112, 1497-1497.	0.6	0
969	Identification of Proteinase 3 (PR3) Gene Overexpression and Protein Delocalization in Core Binding Factor Leukemias as a Mechanism Leading to Increased Chemosensitivity.. Blood, 2008, 112, 204-204.	0.6	0
970	IgG Antibodies against Human Cytomegalovirus Late Protein UL94 in the Pathogenesis of Scleroderma-Like Skin Lesions in Chronic Graft Versus Host Disease. Blood, 2008, 112, 1169-1169.	0.6	0
971	A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment. Blood, 2008, 112, 3186-3186.	0.6	0
972	Erucylphosphocholine, the First Intravenously Applicable Alkylphosphocholine, Induces Cell Cycle Arrest, Apoptosis, and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia.. Blood, 2008, 112, 1330-1330.	0.6	0

#	ARTICLE	IF	CITATIONS
973	The Re-Activation of FoxO3 Transcription Factor in Acute Myeloid Leukaemia Is Responsible for the Induction of a Quiescent Status of Leukaemic Progenitor Cells.. Blood, 2008, 112, 929-929.	0.6	0
974	Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in <i>BCR-ABL1</i>-positive acute lymphoblastic leukemia (ALL) patients. Journal of Clinical Oncology, 2009, 27, 7049-7049.	0.8	0
975	Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience.. Blood, 2009, 114, 2027-2027.	0.6	0
976	Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP.. Blood, 2009, 114, 3957-3957.	0.6	0
977	Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray.. Blood, 2009, 114, 1890-1890.	0.6	0
978	Genome-Wide Screening for Dominant Modifiers in Drosophila Identified New Cluster of Genes Involved in BCR-ABL Signalling and CML Progression.. Blood, 2009, 114, 2186-2186.	0.6	0
979	C-Myc Mediated Regulation of Multidrug Resistance Genes in Chronic Myeloid Leukaemia Cd34+ Cell Progenitors.. Blood, 2009, 114, 3252-3252.	0.6	0
980	Clinical and Biological EFFECTS of 5-Azacitidine FIVE Days/Monthly Schedule IN Symptomatic LOW-RISK (IPSS: 0-1) Myelodysplastic Patient.. Blood, 2009, 114, 4851-4851.	0.6	0
981	Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.. Blood, 2009, 114, 2384-2384.	0.6	0
982	CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.. Blood, 2009, 114, 2174-2174.	0.6	0
983	Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.. Blood, 2009, 114, 3754-3754.	0.6	0
984	90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.. Blood, 2009, 114, 3210-3210.	0.6	0
985	Inactivation of Pre-B Cell Receptor-Mediated Tumor Suppression by Aberrant Splicing in Ph+ Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 579-579.	0.6	0
986	Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.. Blood, 2009, 114, 3283-3283.	0.6	0
987	Abstract 246: Genome-wide screening for dominant modifiers in Drosophila identified new genes involved in BCR-ABL signaling and chronic myeloid leukemia (CML) progression. , 2010, , .		0
988	Abstract 1138: First Application of Whole-Transcriptome Sequencing to a High-Risk Chronic Myeloid Leukemia (CML) Patient at Diagnosis and at the Time of Disease Progression to Blast Crisis (BC). , 2010, , .		0
989	Nuclear Inositide Signalling: Role of PI&EPLCbeta1 in MDS and AML. FASEB Journal, 2010, 24, 80.2.	0.2	0
990	Abstract 656: High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL). , 2010, , .		0



#	ARTICLE	IF	CITATIONS
991	Abstract 1805: Improving on Imatinib for targeted therapy of chronic myeloid leukemia: First line treatment with Nilotinib 800 mg daily results in unprecedentedly high rate of rapid, "deep" and stable molecular responses - Results of a phase 2 trial of the GIMEMA CML working party. , 2010, , .		0
992	Abstract 1804: Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience. , 2010, , .		0
993	First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, "Deep" and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood, 2010, 116, 2720-2720.	0.6	0
994	The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients. Blood, 2010, 116, 3136-3136.	0.6	0
995	Adoptive Immunotherapy with Haploidentical Kir Ligand-Mismatched Natural Killer Cells In Elderly High Risk Acute Myeloid Leukemia Patients: Biological and Clinical Results of A Pilot Study. Blood, 2010, 116, 4287-4287.	0.6	0
996	Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. Blood, 2010, 116, 2279-2279.	0.6	0
997	Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy.. Blood, 2010, 116, 1666-1666.	0.6	0
998	Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT.. Blood, 2010, 116, 1287-1287.	0.6	0
999	A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study. Blood, 2010, 116, 5030-5030.	0.6	0
1000	The Interlaboratory RObustness of Next-Generation Sequencing (IRON) Study: Deep-Sequencing Investigating TET2, CBL, and KRAS Mutations In 4464 Amplicons by An International Group Involving 8 Laboratories.. Blood, 2010, 116, 1665-1665.	0.6	0
1001	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. Blood, 2010, 116, 2281-2281.	0.6	0
1002	Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMoR) at 12 Months. Blood, 2010, 116, 668-668.	0.6	0
1003	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (" 65 years) Ph+ CML Patients " EudraCT Number 2007"005102-42, ClinicalTrials.Gov NCT 00858806.. Blood, 2010, 116, 3412-3412.	0.6	0
1004	The Elevated Expression of FBP1, a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.. Blood, 2010, 116, 3399-3399.	0.6	0
1005	PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG. Blood, 2010, 116, 1770-1770.	0.6	0
1006	DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma "Results from an EBMT Non Interventional Prospective Study. Blood, 2010, 116, 2397-2397.	0.6	0
1007	Evaluation of the GeneXpert Assay for the Monitoring of BCR-ABL Transcript Levels In Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of a Comparison with the Manual and Traditional Manual TaqMan RQ-PCR Assay. Blood, 2010, 116, 4831-4831.	0.6	0
1008	Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients. Blood, 2010, 116, 967-967.	0.6	0

#	ARTICLE	IF	CITATIONS
1009	Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.. Blood, 2010, 116, 3441-3441.	0.6	0
1010	Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma. Blood, 2010, 116, 3956-3956.	0.6	0
1011	Extreme Variability of FIP1L1-PDGFRalpha Transcripts In CEL: Analysis of 32 Patients Enrolled In HES0203 Italian Clinical Trial and Correlation with Clinical and Molecular Response After 5 Years Follow-up. Blood, 2010, 116, 1986-1986.	0.6	0
1012	Abstract 310:BCR-ABL1transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method. , 2011, , .		0
1013	Abstract 5448: Pharmacogenetics of drug transporters may be useful to identify chronic myeloid leukemia patients who are less likely to achieve molecular responses to imatinib: Implications for treatment optimization in the era of new tyrosine kinase inhibitors. , 2011, , .		0
1014	Abstract 2237: Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience. , 2011, , .		0
1015	Abstract 3811: A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL). , 2011, , .		0
1016	Abstract 309: Whole-transcriptome sequencing in chronic myeloid leukemia reveals novel gene mutations that may be associated with disease pathogenesis and progression. , 2011, , .		0
1017	The More Effective and the More (bio) Similar: Plerixafor and Filgrastim XMO2 (tevagastrim) As First Line PBSC Mobilization Strategy in Patients with Multiple Myeloma and Lymphomas Candidate to ABMT. Blood, 2011, 118, 2994-2994.	0.6	0
1018	TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia. Blood, 2011, 118, 1484-1484.	0.6	0
1019	ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112. Blood, 2011, 118, 2574-2574.	0.6	0
1020	Efficacy of 90yttrium-ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma,. Blood, 2011, 118, 3713-3713.	0.6	0
1021	A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM). Blood, 2011, 118, 805-805.	0.6	0
1022	Mature Circulating Endothelial Cells and Progenitors in Patients with Chronic Gvhd. Blood, 2011, 118, 4700-4700.	0.6	0
1023	Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,. Blood, 2011, 118, 3775-3775.	0.6	0
1024	Abstract 1873: Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplifiedMDM4and/or deletedp53. , 2012, , .		0
1025	Abstract 1884: Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology. , 2012, , .		0
1026	Abstract 4694: The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
1027	Abstract 1772: Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL). , 2012, , .		0
1028	PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. Blood, 2012, 120, 1749-1749.	0.6	0
1029	Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients. Blood, 2012, 120, 4787-4787.	0.6	0
1030	Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients. Blood, 2012, 120, 1289-1289.	0.6	0
1031	Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL).. Blood, 2012, 120, 2497-2497.	0.6	0
1032	What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study "RefoLL" by the Fondazione Italiana Linfomi (FIL) On 548 Patients. Blood, 2012, 120, 154-154.	0.6	0
1033	Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients. Blood, 2012, 120, 4951-4951.	0.6	0
1034	Abstract 3749: Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease.. , 2013, , .		0
1035	Abstract 3415: SIRT regulates the molecular interaction between c-MYC and HIF-1 $\alpha$ in multiple myeloma.. , 2013, , .		0
1036	Abstract 4632: Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain in Philadelphia-positive leukemias.. , 2013, , .		0
1037	Abstract 4700: Clinical outcome of T-acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL): the Bologna experience.. , 2013, , .		0
1038	Abstract 4051: Loss of nuclear beta catenin, following chibby enforced expression, activates endoplasmic reticulum stress in cells expressing the BCR-ABL1 fusion gene of chronic myeloid leukemia.. , 2013, , .		0
1039	Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia. Blood, 2013, 122, 3987-3987.	0.6	0
1040	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. Blood, 2013, 122, 1486-1486.	0.6	0
1041	Genomic Instability and Activation Of The DNA Damage Response Pathway Is An Independent Predictor Of Poor Prognosis, Is Associated With MYC Expression and Is a Promising Target For Therapy In Diffuse Large B Cell Lymphoma. Blood, 2013, 122, 3015-3015.	0.6	0
1042	Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harboring T315I Mutation: The Bologna Experience. Blood, 2013, 122, 3911-3911.	0.6	0
1043	Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4. Blood, 2013, 122, 1855-1855.	0.6	0
1044	Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. Blood, 2013, 122, 2659-2659.	0.6	0

#	ARTICLE	IF	CITATIONS
1045	Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain. Blood, 2013, 122, 3986-3986.	0.6	0
1046	Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients. Blood, 2013, 122, 2289-2289.	0.6	0
1047	PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use.. Journal of Clinical Oncology, 2014, 32, 7113-7113.	0.8	0
1048	Abstract 3608: HIF-1 $\alpha$ inhibition blocks the cross talk between multiple myeloma plasmacells and tumour microenvironment. , 2014, , .		0
1049	Abstract 570:Tp53mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome. , 2014, , .		0
1050	Abstract 3884: Gene expression profiling and copy number alterations of circulating clonotypic B cells of multiple myeloma newly diagnosed patients reveals pathways potentially involved in the development and in the disease persistence. , 2014, , .		0
1051	Abstract 3886: Clec12a: A new AML stem cell-associated antigen. , 2014, , .		0
1052	Abstract CT312: Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience. , 2014, , .		0
1053	Abstract 5595: Impact of p53 impaired function on outcomes of multiple myeloma patients carrying deleted TP53 and/or amplified MDM4. , 2014, , .		0
1054	Abstract LB-105:In vitroandin vivosingle-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. , 2014, , .		0
1055	Abstract 2243: Gene expression signature of aneuploidy in acute myeloid leukemia. , 2014, , .		0
1056	SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacididine Therapy in MDS and AML Patients. Blood, 2014, 124, 1030-1030.	0.6	0
1057	Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing. Blood, 2014, 124, 2259-2259.	0.6	0
1058	Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis. Blood, 2014, 124, 1856-1856.	0.6	0
1059	Key Immune Cell Subsets Are Dysregulated in Patients with Myelofibrosis. Blood, 2014, 124, 5580-5580.	0.6	0
1060	Targeting Lon Protease Activity Promotes Growth Inhibition and Apoptosis in Acute Myeloid Leukemia Cell Lines. Blood, 2014, 124, 5130-5130.	0.6	0
1061	Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia. Blood, 2014, 124, 2352-2352.	0.6	0
1062	Mutations and Long-Term Outcome of 217 Young Patients with Essential Thrombocythemia or Early Primary Myelofibrosis. Blood, 2014, 124, 3190-3190.	0.6	0

#	ARTICLE	IF	CITATIONS
1063	A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis. Blood, 2014, 124, 3188-3188.	0.6	0
1064	Cellular Reprogramming Erases Aberrant DNA Methylation and the Malignant Phenotype in Chronic Myeloid Leukemia. Blood, 2014, 124, 4524-4524.	0.6	0
1065	A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM). Blood, 2014, 124, 3400-3400.	0.6	0
1066	Abstract 4248: A long tail of sub-clonal TP53 mutations emerged by ultra-deep sequencing of newly diagnosed multiple myeloma (MM). , 2015, , .		0
1067	Abstract 4848: SNP array reveals a new deletion of JAK2 in AML patients. , 2015, , .		0
1068	Abstract B03: Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome.. , 2015, , .		0
1069	Abstract 4835: A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1. , 2015, , .		0
1070	Abstract 4906: TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome. , 2015, , .		0
1071	Abstract 1521: High-throughput molecular profiling of Multiple Myeloma clonotypic CD19+ B cells highlights pathways potentially involved in the disease endurance. , 2015, , .		0
1072	Abstract 5491: Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience. , 2015, , .		0
1073	Abstract 3957: Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene. , 2015, , .		0
1074	Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients. Blood, 2015, 126, 3198-3198.	0.6	0
1075	Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia. Blood, 2015, 126, 2600-2600.	0.6	0
1076	Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia. Blood, 2015, 126, 3837-3837.	0.6	0
1077	JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. Blood, 2015, 126, 1614-1614.	0.6	0
1078	Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2015, 126, 2513-2513.	0.6	0
1079	Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis. Blood, 2015, 126, 2623-2623.	0.6	0
1080	Bone Marrow (BM) Microenvironment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib. Blood, 2015, 126, 1570-1570.	0.6	0

#	ARTICLE	IF	CITATIONS
1081	A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene. Blood, 2015, 126, 1356-1356.	0.6	0
1082	A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium. Blood, 2015, 126, 3840-3840.	0.6	0
1083	Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia. Blood, 2015, 126, 1573-1573.	0.6	0
1084	The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 2478-2478.	0.6	0
1085	An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival. Blood, 2015, 126, 24-24.	0.6	0
1086	Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells. Blood, 2015, 126, 2580-2580.	0.6	0
1087	Pharmacological interaction and side effects in oncohaematology: a retrospective observational study.. Journal of Clinical Oncology, 2016, 34, e18235-e18235.	0.8	0
1088	Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis.. Journal of Clinical Oncology, 2016, 34, 7044-7044.	0.8	0
1089	Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO).. Journal of Clinical Oncology, 2016, 34, 7043-7043.	0.8	0
1090	Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT).. Journal of Clinical Oncology, 2016, 34, e18520-e18520.	0.8	0
1091	Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and Tj ETQq1 1 0.784314 rgBT /Overleukemia (AML).. Journal of Clinical Oncology, 2016, 34, e18521-e18521.	0.8	0
1092	Abstract 368: Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy. , 2016, , .		0
1093	Abstract 3582: Chromothripsis in AML patients: A new mechanism of cancer initiation and progression. , 2016, , .		0
1094	Abstract 113: Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia. , 2016, , .		0
1095	Abstract 3189: The alternate activation of hedgehog pathway, either in CD138+ or in CD138-CD19+ multiple myeloma primary cells, impacts on disease outcome. , 2016, , .		0
1096	Abstract 5022: The selection of TP53 sub-clonal variants over time identifies MM patients with adverse clinical outcome. , 2016, , .		0
1097	Abstract 4507: New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients. , 2016, , .		0
1098	The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. Blood, 2016, 128, 3097-3097.	0.6	0

#	ARTICLE	IF	CITATIONS
1099	One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study. <i>Blood</i> , 2016, 128, 5423-5423.	0.6	0
1100	Chemotherapy-Dependent ATP Release from Leukemia Dying Cells Induces Indoleamine 2,3-Dioxygenase 1 in Dendritic Cells. <i>Blood</i> , 2016, 128, 3711-3711.	0.6	0
1101	Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations. <i>Blood</i> , 2016, 128, 1678-1678.	0.6	0
1102	Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis. <i>Blood</i> , 2016, 128, 1677-1677.	0.6	0
1103	Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with This May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR). <i>Blood</i> , 2016, 128, 3096-3096.	0.6	0
1104	A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line. <i>Blood</i> , 2016, 128, 3076-3076.	0.6	0
1105	Signals of the Inflammatory Microenvironment Promote a Mutation-Associated Functional Dysregulation of the Circulating Megakaryocyte Progenitors of Myelofibrosis. <i>Blood</i> , 2016, 128, 3142-3142.	0.6	0
1106	Copy number variants signature in two patients with relapsed acute promyelocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23207-e23207.	0.8	0
1107	Microarray analysis to identify novel copy number alterations in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11622-11622.	0.8	0
1108	Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11611-11611.	0.8	0
1109	Abstract 3936: A branching evolution model at relapse characterizes multiple myeloma patients who responded to upfront combination therapy including new drugs. , 2017, , .		0
1110	Abstract 294: Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia. , 2017, , .		0
1111	Abstract 4671: Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients. , 2017, , .		0
1112	Abstract 2451: Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia. , 2017, , .		0
1113	Abstract 1758: A more mature immunophenotypic makeup of multiple myeloma clone(s) at diagnosis correlates with a higher genomic instability. , 2017, , .		0
1114	Abstract 515: Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients. , 2017, , .		0
1115	Abstract 3311: The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up. , 2017, , .		0
1116	Abstract 3472: Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
1117	Abstract 2539: Antiapoptotic gene expression signature reveals a combined talk to prevent apoptosis: A model to choose the proper BH-3 mimetic drug. , 2018, , .		0
1118	Abstract 2176: Whole-genome analysis of CNAs identifies four main evolution trajectories in multiple myeloma (MM) patients front-line treated with PI-based regimens. , 2018, , .		0
1119	Abstract 1872: Pharmacological inhibition of WIP1 sensitizes AML cells to MDM2 inhibitors. , 2018, , .		0
1120	Abstract 3387: The pliancy of plasma cell differentiation status conceals a gradient of chromosomal instability in newly diagnosed multiple myeloma patients. , 2018, , .		0
1121	Abstract 3613: Lab-on-a-chip-based in-vitro functional profiling proves to be effective in predicting therapy outcome in AML patients. , 2018, , .		0
1122	Abstract 2951: Gene expression profiling identifies new adult "triple-negative" acute lymphoblastic leukemia (ALL) subgroups. , 2018, , .		0
1123	Abstract 656: Distinct pattern of alterations in TP53 mutated/deleted and wild-type high risk acute myeloid leukemia (AML) patients: Identification of new "targetable" genes/pathways. , 2018, , .		0
1124	Abstract 3788: Antigen presentation by MHC-I molecule and immune escape in acute myeloid leukemia with high burden of genomic aberrations. , 2018, , .		0
1125	Leukemia cutis in a Ph+ ALL patient treated with ponatinib. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 730-731.	0.8	0
1126	A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups. Blood, 2018, 132, 5284-5284.	0.6	0
1127	Study on Sucrosomial <sup>®</sup> Iron Endocytosis-Mediated Uptake and Enterocytes Release. Blood, 2018, 132, 4892-4892.	0.6	0
1128	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted. Blood, 2018, 132, 1726-1726.	0.6	0
1129	Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics. Blood, 2018, 132, 2748-2748.	0.6	0
1130	Bitter Taste Receptors System Is Expressed and Functional in Both HSCs and Leukemic Cells. Blood, 2018, 132, 2560-2560.	0.6	0
1131	Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy. Blood, 2018, 132, 4347-4347.	0.6	0
1132	The Malignant Hemopoietic Clone of Triple Negative Patients with Myelofibrosis Shows in Vitro Functional Defects but Is Highly Responsive to the Pro-Survival Signals of Circulating Autologous Microvesicles. Blood, 2018, 132, 4334-4334.	0.6	0
1133	Up-Regulation of Immune Tolerance Genes in Leukemic Mesenchymal Stromal Cells Is Induced By Acute Myeloid Leukemia Cells through an IFN-Gamma-Dependent Inflammatory Signaling. Blood, 2018, 132, 2579-2579.	0.6	0
1134	Unexpected Low Expression of Platelet Fibrinogen Receptor in Patients with Chronic Myeloproliferative Neoplasms: How Does It Change with Aspirin?. Blood, 2018, 132, 1794-1794.	0.6	0



#	ARTICLE	IF	CITATIONS
1135	Evaluation of prognostic role of inflammatory index in glioblastoma multiforme patients undergoing to concomitant radio-chemotherapy.. Journal of Clinical Oncology, 2019, 37, e13549-e13549.	0.8	0
1136	PS1437 SETD2-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS. HemaSphere, 2019, 3, 662-663.	1.2	0
1137	PS1461 FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES. HemaSphere, 2019, 3, 673.	1.2	0
1138	Abstract 2140: A new adult Philadelphia negative acute lymphoblastic leukemia subgroup: Novel molecular markers. , 2019, , .		0
1139	Abstract 473: Higher levels of genomic complexity correlates with an advanced plasma cell differentiation status in newly diagnosed multiple myeloma patients. , 2019, , .		0
1140	Abstract 470: Chromosomal instability and bad prognosis both connote a multiple myeloma (MM) sub-type carrying 13qCN loss and 1qCN gain. , 2019, , .		0
1141	Abstract 5255: Breast cancer subtype classification using a multi-gene expression profile. , 2019, , .		0
1142	Abstract 2964: Pharmacological inhibition of WIP1 by GSK2830371 sensitizes AML cells to MDM2 inhibitor Nutlin-3a. , 2019, , .		0
1143	IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease. Blood, 2021, 138, 4446-4446.	0.6	0
1144	Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol. Blood, 2020, 136, 34-35.	0.6	0
1145	New strategies for selection of unrelated bone marrow donors. Bone Marrow Transplantation, 1993, 11 Suppl 1, 31-2.	1.3	0
1146	Bone marrow of a patient with acute non-lymphoblastic leukaemia associated with the t(1;7)(p11;p11) chromosomal translocation. Haematologica, 2002, 87, EIM08.	1.7	0
1147	Abstract 3100: Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+ patients: The bologna compassionate program experience. , 2019, , .		0
1148	Abstract 1914: Acute myeloid leukemia cell and stem-progenitor cell behavior studied in mimetic bone marrow microenvironment. , 2019, , .		0
1149	Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. Cancers, 2022, 14, 3012.	1.7	0